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Vitamin	  D	  Inhibits	  Expression	  of	  Protein	  Arginine	  Deiminase	  2	  and	  4	  in	  Experimental	  
Autoimmune	  Encephalomyelitis	  Model	  of	  Multiple	  Sclerosis	  
	  
Multiple	   sclerosis	   (MS)	   is	   a	   disabling	   disease	   that	   afflicts	   an	   estimated	   two	  
million	   people	   worldwide.	   The	   disease	   is	   characterized	   by	   degradation	   of	   the	  myelin	  
sheath	   that	   insulates	   neurons	   of	   the	   central	   nervous	   system	   manifesting	   as	   a	  
heterogeneous	  collection	  of	  symptoms.	  Two	  enzymes,	  protein	  arginine	  deaminases	  type	  
2	   and	   4	   (PAD2	   and	   PAD4)	   have	   been	   implicated	   to	   play	   an	   etiologic	   role	   in	  
demyelination	  and	  neurodegeneration	  by	  catalyzing	  a	  post-­‐translational	  modification	  of	  
arginine	   peptide	   residues	   to	   citrulline.	   The	   pathogenesis	   of	  MS	   is	   poorly	   understood,	  
though	  vitamin	  D	  deficiency	  is	  a	  well-­‐associated	  risk	  factor	  for	  developing	  the	  disorder.	  
Using	   the	   experimental	   autoimmune	   encephalomyelitis	   (EAE)	   model	   of	   MS	   we	  
demonstrate	  vitamin	  D	   treatment	   to	  attenuate	  over-­‐expression	  of	  PAD	  2	  and	  4	   in	   the	  
brain	   and	   spine	   during	   EAE.	   In	   addition,	   we	   identify	   two	   molecules	   produced	   by	  
peripheral	  immune	  cells,	  IFNɣ	  and	  IL-­‐6,	  as	  candidate	  signaling	  molecules	  that	  induce	  PAD	  
expression	  in	  the	  brain.	  We	  demonstrate	  vitamin	  D	  treatment	  to	  inhibit	  IFNɣ	  mediated	  
up	  regulation	  of	  PAD2	  and	  PAD4	  both	  directly	  within	  the	  brain	  and	  by	  modulating	  PAD-­‐
inducing	   cytokine	   production	   by	   infiltrating	   immune	   cells.	   These	   results	   provide	  
neuroprotective	   rational	   for	   the	   supplementation	   of	   vitamin	   D	   in	  MS	   patients.	   More	  
importantly,	  these	  results	  imply	  an	  epigenetic	  link	  between	  vitamin	  D	  deficiency	  and	  the	  
pathogenesis	  of	  MS	  that	  merits	  further	  investigation.	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  Gallagher,	  Ph.D.	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Multiple	  Sclerosis,	  a	  Heterogeneous	  Disorder 
Multiple	  sclerosis	   (MS)	   is	  a	  disabling	  disorder	  that	  afflicts	  over	  2	  million	  people	  
worldwide	   (Anderson	   et	   al.,	   1992).	   The	   heterogeneous	   disorder	   is	   characterized	   by	  
degradation	   of	   the	   myelin	   sheath	   and	   axonal	   loss	   in	   neurons	   of	   the	   central	   nervous	  
system	  (CNS)	  resulting	   in	  a	  collection	  of	  physical	  disabilities	  and	  cognitive	   impairment.	  
The	   diverse	   pathophysiology	   of	   MS	   is	   classified	   into	   four	   clinical	   immunopatterns	  
involving	  various	  degrees	  of	  inflammation,	  gliosis	  and	  neurodegeneration	  (Popescu	  and	  
Pirko,	  2013).	  The	  disorder	  is	  studied	  in	  several	  animal	  models	  that	  collectively	  reflect	  the	  
heterogeneity	  of	  the	  disorder	  (Moscarello	  et	  al.,	  2013).	  Classically,	  MS	  is	  considered	  an	  
autoimmune	  disease	  modeled	  by	  experimental	  autoimmune	  encephalomyelitis	  (EAE)	  in	  
which	  peripheral	   immune	  cells	  cross	  the	  blood	  brain	  barrier	  and	  react	  with	  the	  myelin	  
sheath	   under	   direction	   of	   CNS-­‐reactive	   Th1/Th17	   cells	   resulting	   in	   neuroinflammation	  
(Robinson	   et	   al.,	   2014).	   However,	   in	   several	   animal	   models	   of	   MS	   including	   the	  
neurotoxic	   cuprizone	   model	   (Star	   et	   al.,	   2012),	   the	   transgenic	   ND4	   mouse	   model	  
(Mastronardi	   et	   al.,	   1993),	   and	   the	   viral	   Theiler’s	   urine	   encephalomyelitis	   model	  
(Fujinami,	  2011)	  neurodegenerative	  stress	  precedes	  peripheral	  immune	  cell	  invasion	  of	  
the	   CNS.	   Diffuse	   neurodegeneration	   apart	   from	   plaques	   is	  well	   observed	   in	  MS	   brain	  
(Haider	  et	  al.,	  2014).	  	  These	  results	  suggest	  degenerative	  mechanisms	  to	  work	  in	  concert	  
with	  or	  to	  even	  potentiate	  demylination	  by	  the	  adaptive	  immune	  response	  of	  invading	  
peripheral	  immune	  cells.	  
2	  
	  
Protein	  Arginine	  Deaminases	  Expression	  in	  Brain	  and	  Peripheral	  Immune	  Cells	  
One	   molecular	   target	   at	   the	   intersection	   of	   auto-­‐inflammation	   by	   peripheral	  
immune	   cells	   and	   inflammation-­‐independent	   oligodendrocyte	   degeneration	   is	   the	  
protein	  arginine	  deiminase	  (PAD)	  family	  of	  enzymes.	  Over-­‐expression	  and	  up-­‐regulation	  
of	  PAD	  activity	  are	  associated	  both	  with	  autoimmune	  diseases,	  such	  as	  Lupus	  (Nissinen	  
et	  al.,	  2003;	  Knight	  et	  al.,	  2013)	  and	  rheumatoid	  arthritis	  (Jones	  et	  al.,	  2009;	  Nissinen	  et	  
al.,	  2003),	  as	  well	  as	  neurodegenerative	  diseases	   including	  Alzheimer’s	  (Ishigami	  et	  al.,	  
2005;	   (Whiteley,	   2014),	   Parkinson’s	   (Nicholas,	   2011)	   and	   prions	   disease	   (Jang	   et	   al.,	  
2013).	  Of	  the	  five	  enzymes	  that	  compose	  the	  family,	  only	  PAD2	  and	  PAD4	  enzymes	  are	  
expressed	  both	  in	  the	  CNS	  and	  peripheral	  immune	  cells	  (Vossenaar	  et	  al.,	  2003).	  PAD	  2	  
and	  PAD4	  catalyze	  an	  irreversible	  and	  calcium-­‐dependent	  post-­‐translational	  deimination	  
of	  peptidyl	  arginine	  residues	  to	  citrulline	  resulting	  in	  a	  loss	  of	  cationical	  charge	  and	  mass	  
at	  the	  converted	  residue.	  PAD4	  contains	  a	  nuclear	   localization	  sequence	  and	  has	  been	  
demonstrated	   to	   citrullinate	   histone	   H3	   under	   stimulation	   of	   TNFα	   where	   it	   is	  
implicated	  to	  play	  a	  role	   in	  oligodendrocyte	  apoptosis	   (Mastronardi	  et	  al.,	  2006).	  Both	  
enzymes	   localize	   to	   the	   intracellular	   space	   between	   oligodendrocytes	   and	   neurons	  
(Wood	  et	  al.,	  2008),	  with	  PAD2	  contributing	  to	  the	  majority	  of	  citrullination	  (Beers	  et	  al.,	  





PAD	  Activity	  During	  MS	  
Expression	   of	   both	   PAD2	   and	   PAD4,	   total	   PAD	   activity	   and	   the	   amount	   of	  
citrullinated	   protein	   are	   all	   up	   regulated	   in	   the	   brain	   during	  MS	   (Wood	   et	   al.,	   2008)	  
where	   the	   amount	   of	   citrullinated	  myelin	   basic	   protein	   (MBP)	   correlates	  with	   clinical	  
severity.	   An	   average	   of	   18%	   of	   MBP	   extracted	   from	   control	   adult	   normal	   appearing	  
white	  matter	  (NAWM)	  has	  been	  demonstrated	  to	  be	  citrullinated	  at	  the	  C-­‐8	  moiety	  as	  
compared	  to	  45%	  of	  MBP	  in	  NAWM	  during	  chronic	  MS	  (Moscarello	  et	  al.,	  1994).	  During	  
Marburg’s	  Disease,	  or	  acute	  MS,	   the	  proportion	  of	  citrullinated	  MBP	   increases	   to	  90%	  
(Wood	  et	  al.,	  1996).	  Hypercitrullination	   in	   the	  CNS	  occurs	   in	   several	  animal	  models	  of	  
MS	   including	   murine	   experimental	   autoimmune	   encephalomyelitis	   (Nicholas	   et	   al.,	  
2005;	  Raijmakers	  et	  al.,	  2005)	  as	  well	  as	  models	   that	  are	  not	  Th1	  cell	  mediated.	  PAD2	  
over-­‐expression	  precedes	  demyelination	  and	  protein	  citrullination	  by	  one	  month	  in	  ND4	  
mice	   that	   express	   70	   copies	   of	   the	   cDNA	   for	   the	   myelin	   proteolipid	   DM20,	   implying	  
citrullination	  to	  play	  an	  etiologic	  role	   in	  the	  biochemistry	  of	  demylenation	  (Moscarello	  
et	   al.,	   2002).	   PAD2	   over-­‐expression	   alone	   is	   sufficient	   to	   cause	   spontaneous	  
demyelination	  at	   six	  months	  of	   age	   in	  mice	   transfected	  with	  30	   copies	  of	  PAD2	  cDNA	  
under	  the	  MBP	  promoter	  (Musse	  et	  al.,	  2008).	  Finally,	  irreversible	  inhibition	  of	  the	  PAD	  
family	   enzymes	   with	   2-­‐chloroacetamidine	   attenuates	   or	   entirely	   resolves	   clinical	  
symptoms	  in	  four	  independent	  animal	  models	  of	  MS	  (Moscarello	  et	  al.,	  2013).	  Together,	  
these	   results	   indicate	   an	   important	   role	   for	   PAD	   enzyme	   activity	   across	   a	   variety	   of	  
demyelination	  processes.	   
	  
4	  
PADs	  in	  Auto-­‐Inflammation	  and	  Oligodendrocyte	  Apoptosis	  
Citrullination	  of	  MBP	  and	  other	  myelin	  sheath	  proteins	  by	  PAD2	  has	  potential	  to	  
cause	   neurodegeneration	   independent	   of	   infiltrating	   immune	   cells	   as	   well	   as	   trigger	  
enhanced	   auto-­‐inflammation	   against	   the	   myelin	   sheath	   by	   infiltrating	   immune	   cells.	  
Moscarello	   has	   demonstrated	   less-­‐cationically	   charged	   MBP	   to	   loose	   its	   compact	  
tertiary	  structure	  and	  cause	  poor	  lipid	  bilayer	  packing	  by	  several	  techniques	  including	  X-­‐
ray	  diffraction	   (Brady	  et	  al.,	  1981),	  electron	  spin	   resonance	   (Natl	  et	  al.,	  1982),	   circular	  
dichroism	  (Epand	  and	  Wheeler,	  1974)	  and	  NMR	  (Deber	  et	  al.,	  1986).	  Citrullinated	  MBP	  
dissociates	  more	  readily	  from	  the	  lipid	  bilayer	  than	  other	  modified	  forms	  of	  the	  protein.	  
In	   vitro	   recapitulation	   of	   this	   dissociation	   in	   mixed	   microglia/oligodendrocyte	   culture	  
results	   in	   iNOS	   induction	   in	   microglia	   causing	   apoptosis	   of	   oligodendrocytes	   via	  
mitochondrial	   pathway	   (Shanshiashvili	   et	   al.,	   2012).	   These	   observations	   demonstrate	  
citrullinated	  MBP	   to	   play	   an	   etiopathic	   role	   in	   demyelination	   independent	   of	   Th1	   cell	  
mediated	  inflammation.	  	  
Citrullinated	  MBP	  also	  represents	  a	  novel	  epitope	  to	   infiltrating	   leukocytes	  and	  
increases	   the	   repertoire	   of	   auto-­‐reactive	   T	   cells	   under	   the	   Th1	   model	   of	   MS.	   T	   cell	  
polarization	   by	   citrullinated	  MBP	  occurs	   preferentially	   in	  MS	   patients	   as	   compared	   to	  
controls	  suggesting	  the	  increased	  myelin	  citrullination	  during	  MS	  to	  exacerbate	  Th1	  cell	  
mediated	   inflammation	  by	   infiltrating	   leukocytes	   in	   the	  MS	  brain	   (Deraos	  et	  al.,	  2008;	  
Tranquill	  et	  al.,	  2000).	  This	  exacerbation	  of	   the	  Th1	  response	  by	  the	  peptidyl	  citrulline	  
epitope	   in	  myelin	   sheath	  proteins	  can	  be	   recapitulated	   in	   the	  EAE	  model	  of	  MS.	  Mice	  
with	  EAE	  that	  are	  injected	  with	  T	  cells	  activated	  by	  citrullinated	  myelin	  oligodendrocyte	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glycoprotein	   (MOG)	  have	  been	   shown	   to	  develop	  exaggerated	  pathology	   (Carrillo-­‐vico	  
et	   al.	   2014).	   How	   PADs	   become	   over-­‐expressed	   in	   order	   to	   contribute	   to	  
oligodendrocyte	   degeneration	   and	   Th1	   mediated	   inflammation	   during	   MS	   is	   poorly	  
understood.	  	  
	   	  
PADs	  and	  Vitamin	  D	  
The	   etiology	   of	   MS	   is	   unknown,	   but	   one’s	   risk	   for	   developing	   the	   disorder	   is	  
thought	   to	   involve	   a	   genetic	   predisposition	   triggered	   by	   a	   number	   of	   interacting	  
environmental	   risk	   factors	   including	   smoking,	   viral	   infection	  and	  vitamin	  D	   status	   that	  
contribute	   to	   one’s	   risk	   for	   developing	   MS	   from	   conception	   into	   adulthood	   (Pierrot-­‐
deseilligny	   and	   Souberbielle,	   2013).	   Maternal	   parent	   of	   origin	   effects,	   birth	   month	  
effects	   and	   differences	   in	   occurrence	   of	   the	   disorder	   between	   monozygous	   twins	  
further	  imply	  epigenetic	  aetiologic	  mechanisms	  that	  can	  be	  imprinted	  in	  utero	  and	  are	  
highly	  stable,	  such	  as	  DNA	  methlyation	  patterns.	  The	  CpG	  island	  of	  the	  PAD2	  promoter	  
has	  been	  demonstrated	   to	  be	  hypomethlyated	   in	  NAWM	  of	  MS	  brain	   (Mastronardi	  et	  
al.,	  2007).	  We	  speculate	  that	  hypomethlyation	  of	  the	  PAD2	  promoter	  region	  mediated	  
by	  an	  environmental	  risk	  factor	  early	  in	  life	  might	  predispose	  an	  individual	  to	  PAD2	  over-­‐
expression	  and	  demyelination	   later	   in	   life.	  A	  vitamin	  D	  receptor	  binding	  site	   is	   located	  
within	  an	  exon	  of	  PAD3	  clustered	  by	  PAD2	  and	  PAD4	  on	  chromosome	  one.	  The	  genes	  
have	   previously	   been	   demonstrated	   responsive	   to	   the	   vitamin	   D	   receptor	   (VDR)-­‐
1,25(OH)2D3	  complex	  in	  keratinocytes	  (Lu	  et	  al.,	  2005).	  	  Chip	  analysis	  has	  revealed	  the	  
VDR-­‐1,25(OH)2D3	   complex	   to	   repress	   expression	   of	   certain	   genes	   by	   mediating	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hypermethylation	   of	   target	   gene	   promoter	   regions	   (Fu	   et	   al.,	   2013),	   providing	   a	  
plausible	  mechanism	  for	  vitamin	  D	  to	  directly	  repress	  PAD	  expression.	  
	  
Vitamin	  D	  and	  MS/EAE	  
The	   association	   between	   vitamin	   D	   status	   and	   risk	   of	   developing	   MS	   is	   well	  
characterized	  (Pierrot-­‐deseilligny	  and	  Souberbielle	  2013;	  (Simon,	  Munger	  and	  Ascherio,	  	  
2012)	  and	  first	  suggested	  quite	  some	  time	  ago	  (Goldberg,	  1974).	  The	  prevalence	  of	  the	  
disorder	   is	  stratified	  geographically	  with	  the	  highest	  prevalence	  far	  north	  and	  south	  of	  
the	   equator	   and	   lowest	   prevalence	   near	   the	   equator	   (Freedman,	   Dosemeci,	   and	  
Alavanja,	  2000).	  Since	  de	  novo	  vitamin	  D	  synthesis	  from	  7-­‐dehydrocholesterol	  requires	  
exposure	   of	   the	   skin	   to	   UV	   light,	   the	   latitude-­‐dependent	   distribution	   of	   MS	  
demonstrates	   increased	   risk	   for	   developing	   MS	   in	   populations	   geographically	  
predisposed	   to	  be	   vitamin	  D	  deficient.	  Variants	  of	   vitamin	  D	   related	  genes	  have	  been	  
investigated	   with	   suggestive	   results.	   Most	   notably,	   rare	   variants	   of	   the	   vitamin	   D	  
activating	   enzyme	   CYP27B1,	   associated	   with	   decreased	   25(OH)D	   activation,	   to	  
1,25(OH)2D3	   carry	   an	   increased	   risk	   for	   developing	   MS	   suggesting	   a	   causal	   role	   for	  
vitamin	   D	   deficiency	   in	   MS	   pathogenesis	   (Ramagopalan	   et	   al.,	   2011).	   Individuals	  
deficient	   in	   circulating	  25(OH)D	  have	   a	   greater	   risk	   for	   developing	  MS	   (Munger	   et	   al.,	  
2014)	  and	   in	  patients	  newly	  diagnosed,	   vitamin	  D	   status	  predicts	   the	  extent	  of	   future	  
disability	  (Smolders	  et	  al.,	  2008)	  and	  risk	  of	  new	  T2	  lesions	  (Mowry	  et	  al.,	  2012).	  Vitamin	  
D	  supplementation	  has	  been	  shown	  to	  increase	  long-­‐term	  memory	  during	  MS	  (Koven	  et	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al.,	  2013).	  Most	  MS	  patients	  supplement	  with	  vitamin	  D	  and	  a	  large	  clinical	  trial	  on	  high	  
dose	  vitamin	  D	  on	  disease	  progression	  is	  currently	  underway.	  	  
Immunomodulatory	  effects	  of	  vitamin	  D	  have	  been	  well	  characterized.	  We	  have	  
previously	  demonstrated	   treatment	  with	   the	  active	   form	  of	  vitamin	  D	  1,25(OH)2D3	   to	  
ameliorate	   clinical	   symptoms	   in	   the	   chronic	   EAE	   model	   of	   MS	   by	   regulating	   Th1	  
differentiation	   through	   the	   IFNɣ/IL-­‐12	   axis	   (Bright	   et	   al.,	   2006),	   but	   its	   direct	  
neuroprotective	  effects	  are	  less	  well	  understood	  with	  no	  previous	  study	  relating	  vitamin	  
D	  to	  PAD	  expression	  in	  the	  brain	  during	  MS.	  	  
	   	  
Hypothesis	  
We	   hypothesized	   that	   Vitamin	   D	   attenuates	   chronic	   EAE	   by	   modulating	  
expression	  of	  PAD	  2	  and	  4.	  	  
	   	  
Brief	  Results	  
Using	   the	   chronic	   EAE	  model	   of	  MS,	   we	   demonstrate	   vitamin	   D	   treatment	   to	  
repress	  PAD2	  and	  4	  expression	  in	  the	  brain	  and	  identify	  the	  IFNɣ/IL-­‐12	  axis	  of	  infiltrating	  
peripheral	   immune	   cells	   as	   an	   inducer	   of	   PAD	   expression.	   Our	   results	   demonstrate	  
vitamin	  D	  to	  attenuate	  peripheral	  immune	  cell	  mediated	  induction	  of	  PADs	  in	  the	  brain.	  
In	  addition,	  we	  show	  vitamin	  D	  to	  directly	  inhibit	  PAD	  expression	  in	  the	  brain	  implying	  a	  




METHODS	  &	  MATERIALS	  
	  
Animals	  and	  cells	  
The	   C57BL/6	   mice	   were	   purchased	   from	   Harlan	   Laboratory	   (Indianapolis,	   IN,	  
USA)	   and	   maintained	   in	   the	   animal	   care	   facility	   at	   the	   Indiana	   University	   Health	  
Methodist	   Research	   Institute.	   All	   animal	   use	   protocols	   were	   approved	   by	   IACUC	  
institutional	   review.	   Mixed	   brain	   cell	   and	   spleen	   cell	   cultures	   were	   prepared	   from	  
C57BL/6	  mice	   in	  DMEM	  and	  RPMI	  medium,	   respectively,	   and	   co-­‐cultured	   in	  DMEM.	  T	  
Cell	   cultures	  were	   prepared	   from	   spleens	   of	   C57BL/6	  mice	   in	   RPMI	  medium	   (2	   X	   106	  
cells/ml)	   and	   stimulated	  with	  5	  µg/ml	  of	  Concanavalin	  A	   (Con	  A.)	   (Pharmacia	  Biotech,	  
Uppsla,	   Sweden)	   for	   three	   days.	   RAW	   cells	   obtained	   from	  ATCC	   (Manassas,	   VA,	   USA)	  
were	  cultured	  in	  DMEM.	  All	  cultures	  were	  supplemented	  with	  10%	  heat-­‐inactivaed	  FBS	  
(Gibco	  BRL,	  Rockville,	  MD,	  USA)	  at	  37	  °C	  and	  5%	  CO2.	  	  
	  
Reagents	  
The	  peptide	  [MEVGWYRSPFSRVVHLYRNGK]	  corresponding	  to	  mouse	  MOGp35-­‐55	  
(>96.81%	   pure)	   was	   purchased	   from	   Genemed	   Synthesis	   (San	   Antonio,	   TX,	   USA).	  
1,25(OH)2D3,	  LPS	  and	  ATP	  were	  obtained	  from	  Sigma	  Aldrich	  (St.	  Louis,	  MO,	  USA).	  WST-­‐
1	   (4-­‐[3-­‐(4-­‐iodophenyl)-­‐2-­‐(4-­‐nitrophenyl)-­‐2H-­‐5-­‐tetrazolio]-­‐1,3-­‐benzene	   disulfonate)	   used	  
in	   proliferation	   assays	  was	   purchased	   from	   Roche	   Diagnostics	   (Indianapolis,	   IN,	   USA).	  
Recombinant	   mouse	   IFNɣ,	   IL-­‐17	   and	   IL-­‐6	   were	   purchased	   from	   R&D	   Systems	  
(Minneapolis,	   MN,	   USA).	   The	   High	   Capacity	   cDNA	   Reverse	   Transcription	   kit	   was	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purchased	   from	   Applied	   Biosystem	   (Foster	   City,	   CA,	   USA).	   The	   quantitative	   reverse	  
transcription	   polymerase	   chain	   reaction	   (qRT-­‐PCR)	  master	  mix	   and	   primers	   for	   PADI2	  
(PAD2),	   PADI4	   (PAD4)	   and	   18S	  were	   purchased	   from	  Qiagen	   (Valencia,	   CA,	  USA).	   The	  
rabbit	  anti-­‐citrulline	  antibody	  and	  goat	  anti-­‐rabbit	  Alexa	  Fluor	  antibody	  were	  purchased	  
from	  EMD	  Millipore	  (Billerica,	  MA,	  USA)	  and	  Invitrogen	  (Eugene,	  OR,	  USA),	  respectively.	  
Immobilion-­‐FL	   membranes	   were	   purchased	   from	   EMD	  Millipore	   (Billerica,	   MA,	   USA).	  
The	   SuperSignal	  West	   Pico	   Chemiluminescent	   Substrate	   was	   purchased	   from	   Thermo	  
Scientific	  (Rockford,	  IL,	  USA).	  	  
	  
Induction	  and	  Treatment	  of	  EAE	  
EAE	   was	   induced	   in	   six	   6-­‐	   to	   8-­‐week-­‐old	   female	   mice	   by	   subcutaneous	  
immunization	  with	  100	  µg	  MOGp35-­‐55	  peptide	  in	  150	  µl	  emulsion	  of	  Complete	  Freund’s	  
Adjuvant	  (Difco,	  Detroit,	  MI)	  at	  the	  lower	  dorsum	  on	  days	  0	  and	  7.	  In	  addition,	  the	  mice	  
were	  injected	  intraperiotoneally	  (i.p.)	  with	  100	  ng	  pertussis	  toxins	  in	  100	  µl	  phosphate-­‐
buffered	   saline	   (PBS)	   on	   days	   0	   and	   2.	   The	   mice	   comprising	   the	   treatment	   group	  
received	  (i.p.)	  100	  ng	  1,25(OH)2D3	  in	  25	  µl	  DMSO	  every	  other	  day	  while	  the	  mice	  of	  the	  
EAE	  control	  group	  received	  (i.p.)	  25µl	  DMSO	  alone	  and	  age-­‐matched	  naïve	  females	  were	  
used	  as	  controls.	  
	  
qRT-­‐PCR	  
The	  effect	   of	   1,25(OH)2D3	  on	  PAD2	  and	  PAD4	  mRNA	  was	  determined	  by	  qRT-­‐
PCR.	  To	  characterize	  the	  in	  vivo	  response	  of	  1,25(OH)2D3	  on	  PAD	  expression,	  naïve	  and	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EAE-­‐induced	  mice	  of	  each	   treatment	  group	  were	  sacrificed	  on	  day	  14	   to	   isolate	  brain,	  
spinal	   cord	   and	   spleen	   tissues.	   To	   determine	   the	   spleen	   ex	   vivo	   response	   in	   PAD	  
expression	  to	  neural	  antigen	  stimulation,	  portions	  of	  each	  isolated	  spleen	  were	  pooled	  
within	  treatment	  groups	  and	  cultured	  in	  12-­‐well	  plates	  at	  2	  X	  106	  cells/ml	  with	  RPMI	  in	  
the	   presence	   or	   absence	   of	   10	   µg/ml	   MOGp35-­‐55	   antigen.	   Cells	   and	   culture	  
supernatants	  were	  collected	  after	  72	  hr.	  Next,	  the	  ex	  vivo	  response	  of	  PAD	  expression	  in	  
the	  brain	  by	  immune	  cell	  secreted	  cytokines	  was	  characterized	  by	  culturing	  mixed	  brain	  
cells	  from	  naïve	  mice	  in	  DMEM	  medium	  containing	  10%	  culture	  supernatants	  collected	  
from	  72	  hr	  spleen	  cultures	  of	  naïve,	  EAE	  and	  1,25(OH)2D3-­‐treated	  mice	  sacrificed	  at	  day	  
14.	   The	   in	   vitro	   brain	   expression	   of	   PADs	   in	   response	   to	   secreted	   cytokines	   in	   the	  
presence	  or	  absence	  of	  1,25(OH)2D3	  was	  characterized	  by	  48	  hr	  treatment	  of	  mixed	  cell	  
brain	   cultures	  of	  naïve	  mice	  with	  100	  nM	  1,25(OH)2D3	   in	   the	  presence	  or	  absence	  of	  
10%	  supernatant	  from	  day	  14	  spleen	  cell	  culture	  supernatants	  of	  EAE	  mice.	  	  
Finally,	   mixed	   brain	   cell	   cultures	   of	   naïve	   mice	   were	   treated	   with	   100	   nM	  
1,25(OH)2D3	  in	  the	  presence	  of	  either	  	  2	  ng/ml	  IL-­‐17,	  4	  ng/ml	  IFNɣ,	  or	  2.5	  ng/ml	  IL-­‐6	  for	  
48	  hr.	  IL-­‐17	  and	  IFNɣ	  treated	  mixed	  cell	  brain	  cultures	  were	  stimulated	  with	  1	  µg/ml	  LPS	  
and	  1	  mM	  ATP	  at	  hour	  2	  and	  42,	  respectively.	  Total	  RNA	  from	  all	  tissues	  and	  cells	  was	  
extracted	   and	   quantified	   using	   TRIzol	   reagent	   and	   Quibit	   RNA	   assay	   kit,	   respectively,	  
following	   manufacturer’s	   instructions	   (Invitrogen,	   Madison,	   WI,	   USA).	   Extracted	   RNA	  
was	   reverse	   transcribed	   to	   cDNA	   using	   TaqMan	   reverse	   transcription	   kit	   in	   the	   2720	  
Thermocycler	   and	   then	   amplified	   in	   the	   ABI	   7900	   Fast	   Sequence	   Detection	   System	  
(Applied	   Biosystems,	   Foster	   City,	   CA,	   USA)	   using	   Qiagen	   master	   mix	   with	   probe	   and	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primers.	  PAD	  2	  and	  4	  gene	  expression	  (normalized	  to	  18S)	  was	  calculated	  using	  the	  delta	  
delta	   Ct	   study	   software	   (Applied	   Biosystems,	   Foster	   City,	   CA,	   USA)	   and	   presented	   as	  
relative	  quantity	  compared	  to	  control.	  
	  
Immuno	  Dot	  Blot	  
The	   effect	   of	   1,25(OH)2D3	   on	   citrullination	   in	   the	   spleen	  was	  measured	   using	  
immuno	   dot	   blot.	   Protein	   was	   extracted	   into	   Laemmli	   sample	   buffer	   from	   spleens	  
isolated	  from	  naïve	  or	  EAE-­‐induced	  mice	  treated	  (i.p.)	  every	  other	  day	  with	  either	  100	  
ng	  of	  1,25(OH)2D3	  in	  25µl	  DMSO	  or	  DMSO	  alone.	  Samples	  were	  pooled	  between	  groups	  
and	  loaded	  in	  duplicate	  (5	  µg/600	  µl	  sample	  buffer/well)	  into	  the	  Bio-­‐Dot	  Microfiltration	  
Apparatus	   (Bio-­‐Rad,	   Hercules,	   CA)	   fitted	   with	   a	   PVDF	   membrane.	   Blots	   were	   rinsed	  
three	  times	   for	  20	  min	  each	   in	  TBST,	  blocked	   in	  TBST	  containing	  10%	  milk	   for	  1hr	  and	  
then	   incubated	   over	   night	   at	   4	   °C	   in	   TBST	   containing	   5%	  milk	  with	   either	   rabbit	   anti-­‐
citrulline	   antibody	   (1:500)	   or	  mouse	   anti-­‐ß	   actin	   antibody	   (1:1000).	  Membranes	  were	  
then	  rinsed	  three	  times	  and	  treated	  with	  peroxidase-­‐conjugated	  anti-­‐IgG	  antibodies	   in	  
TBST	   containing	   5%	   milk	   (1:5000)	   for	   2	   hr.	   Blots	   were	   developed	   using	   SuperSignal	  
enhanced	   chemiluminescene	   detection	   system	   and	   imaged	   using	   the	   Alpha	   Innotech	  
Light	   Cabinet	   (San	   Leandro,	   CA,	   USA)	   to	   determine	   average	   density	   of	   each	   dot.	   The	  
relative	  citrullination	  of	  each	  sample	  was	  expressed	  as	  citrulline	  absorbance	  normalized	  





The	  effect	  of	  neural	  antigen	  induced	  stimulation	  and	  1,25(OH)2D3	  treatment	  on	  
immune	   cell	   proliferation	   was	   measured	   using	   WST-­‐1	   assay.	   First,	   the	   ex	   vivo	  
proliferative	   effect	   of	   neural	   antigen	   stimulation	   on	   whole-­‐spleen	   cell	   culture	   was	  
characterized	  from	  spleens	  isolated	  from	  naïve	  and	  EAE	  mice.	  Spleen	  cells	  harvested	  at	  
day	   14	   from	   naïve,	   EAE	   and	   1,25(OH)2D3	   treated	   EAE	   mice	   were	   cultured	   in	   RPMI	  
medium	  for	  96	  hr	  in	  96-­‐well	  tissue	  culture	  plates	  (2X105/200µl/well)	  with	  0,	  2.5,	  5	  or	  10	  
µg/ml	  MOGp35-­‐55.	  Next,	  the	  in	  vitro	  effect	  of	  1,25(OH)2D3	  on	  spleen	  cell	  proliferation	  
was	   determined	   by	   culturing	   spleen	   cells	   isolated	   from	   EAE	   mice	   with	   10	   µg/ml	  
MOGp35-­‐55	   in	  the	  same	  manner	  as	  above	  with	  either	  0,	  5,	  10,	  25,	  50,	  100	  or	  250	  nM	  
1,25(OH)2D3.	  Splenocytes	  were	   isolated	  from	  spleens	  of	  naïve	  animals	  and	  cultured	  in	  
RPMI	  medium	  for	  96	  hr	  in	  96-­‐well	  plates	  (2X105/200µl/well)	  in	  the	  presence	  of	  either	  0,	  
1,	  2.5	  or	  5	  µg/ml	  of	  Con	  A.	  The	  in	  vitro	  effect	  of	  1,25(OH)2D3	  on	  cell	  proliferation	  was	  
determined	  by	  culturing	  splenocytes	  with	  5	  µg/ml	  Con	  A	  and	  either	  10,	  25,	  50	  or	  100	  nM	  
1,25(OH)2D3.	   RAW	   cells	   were	   cultured	   in	   DMEM	  medium	   for	   96	   hr	   in	   96-­‐well	   plates	  
(104/200µl/well)	   in	   the	   presence	   of	   either	   0,	   .5	   or	   1	   µg/ml	   LPS.	   The	   in	   vitro	   effect	   of	  
1,25(OH)2D3	  on	  RAW	  cell	  proliferation	  was	  determined	  by	   culturing	  RAW	  cells	  with	  1	  
µg/ml	  LPS	  and	  10,	  25	  or	  100	  nM	  1,25(OH)2D3.	   In	  all	  proliferation	  assays,	  10	  µl/well	  of	  
WST-­‐1	  reagent	  was	  added	  at	  hour	  90	  before	  reading	  the	  OD	  at	  450	  nm	  during	  hour	  96	  
using	   a	   titer-­‐plate	   reader	   (Alpha	   Diagnostics,	   San	   Antonio,	   TX,	   USA).	   All	   absorbance	  




The	  values	  presented	  are	  mean	  +/-­‐	  standard	  error	  and	  analyzed	  using	  one-­‐way	  
ANOVA	  analysis	  of	   variance	   (and	   linear	   correlation	   in	   the	   case	  of	  proliferation	  assays)	  
using	   Prism	   6.0	   software	   (GraphPad,	   San	   Diego,	   CA,	   USA).	   Significance	   of	   results	   are	  





Vitamin	  D	  Inhibits	  PAD2	  AND	  PAD4	  Expression	  in	  Brain	  and	  Spine	  During	  Chronic	  EAE	  
Earlier	   studies	   have	   shown	   that	   induction	   of	   EAE	   increases	   expression	   and	  
activity	   of	   PAD2	   in	   the	   brain	   during	   EAE	   (Raijmakers	   et	   al.,	   2006)	   and	   that	   treatment	  
with	  1,25(OH)2D3	  alleviates	  clinical	  scores	  of	  disease	  progression	  (Bright	  et	  al.,	  2006a).	  
To	   understand	   the	   effects	   of	   vitamin	   D	   on	   PAD	   expression	   during	   chronic	   EAE	   we	  
compared	  the	  relative	  gene	  expression	  of	  PAD2	   (Fig.	  1A,B,C)	  and	  PAD4	   (Fig.	  1D,E,F)	   in	  
the	  brain,	  spine	  and	  spleen	  between	  naive	  and	  EAE-­‐induced	  C57BL/6	  mice.	  Expression	  
of	   both	   PAD2	   and	   PAD4	   are	   increased	   in	   the	   brain	   and	   spine	   of	   EAE	   animals	   as	  
compared	   to	  naïve.	  The	  most	   robust	   induction	  occurred	   in	   the	  brain	  where	  PAD2	  and	  
PAD4	   increased	   5.2-­‐fold	   (Fig.	   1A,	   p<0.05,	   n=3)	   and	   12.2-­‐fold	   (Fig.	   1D,	   p<0.001,	   n=3),	  
respectively.	  However,	  expression	  of	  each	  gene	  decreased	  in	  the	  spleen	  during	  EAE	  (Fig.	  
1C,F,	  p=not	  significant,	  n=3).	  	  
Next,	   we	   compared	   the	   expression	   of	   PAD2	   and	   PAD4	   between	   chronic	   EAE	  
animals	   injected	   (i.p.)	   every	  other	  day	   from	  day	  0-­‐30	  with	  either	  100	  ng	  1,25(OH)2D3	  
dissolved	  in	  DMSO	  or	  DMSO	  alone.	  Treatment	  with	  1,25(OH)2D3	  decreased	  expression	  
of	  both	  PADs	  during	   chronic	  EAE	   in	  brain	   (Fig.	   1A,D)	   and	   spine	   (Fig.	   1B,E)	   to	   the	   level	  
expressed	   by	   naive	   animals.	   In	   the	   brain,	   1,25(OH)2D3	   treatment	   reduced	   PAD2	   and	  
PAD4	   expression	   5.6-­‐fold	   (Fig.	   1A,	   p<0.05,	   n=3)	   and	   10.4-­‐fold	   (Fig.	   1D,	   p<0.001,	   n=3),	  
respectively.	   In	   the	   spleen,	   1,25(OH)2D3	   treatment	   repression	   of	   each	   gene	   was	   not	  
significant	   (Fig.	   1C,F)	   suggesting	   that	   vitamin	   D	   has	   little	   effect	   on	   PAD	   repression	   in	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immune	   cells.	   These	   results	   demonstrate	   that	   PAD	   expression	   induced	  during	   chronic	  
EAE	  is	  most	  relevant	  to	  the	  brain	  and	  that	  this	  induction	  can	  be	  prevented	  by	  treatment	  
with	  1,25(OH)2D3.	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Fig.	  1.	  Expression	  of	  PADs	  in	  brain,	  spine	  and	  spleen	  during	  EAE	  
(A-­‐C)	   PAD2	   expression	   at	   day	   14	   in	   brain	   (A,	   p<0.05),	   spinal	   cord	   (B),	   and	   spleen	   (C)	  
tissue	   homogenates	   of	   naïve,	   EAE	   and	   1,25(OH)2D3	   treated	   EAE	   mice.	   (D-­‐F)	   PAD4	  
expression	   at	   day	   14	   in	   brain	   (D,	   p<0.001),	   spinal	   cord	   (E)	   and	   spleen	   (F)	   tissue	  
homogenates	  of	  naïve,	  EAE	  and	  1,25(OH)2D3	  treated	  EAE	  mice.	  In	  all	  assays,	  n=3.	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Vitamin	  D	  Inhibits	  Citrullination	  in	  the	  Spleen	  During	  Chronic	  EAE	  
We	  examined	  the	  citrullination	  status	  of	  peripheral	  immune	  cells	  during	  EAE	  by	  
immuno	  dot	  blot	  analysis	  of	  spleen	  protein	  extracts	  pooled	  between	  groups	  of	  animals.	  
As	  shown	  (Fig.	  2A)	  and	  quantified	  (Fig.	  2B),	  more	  citrullinated	  peptides	  were	  detected	  in	  
spleens	  of	  chronic	  EAE	  animals	  as	  compared	  to	  naïve.	  This	  induced	  citrullination	  status	  
observed	  during	  chronic	  EAE	  is	  decreased	  33%	  by	  treatment	  with	  100	  ng	  of	  1,25(OH)2D3	  
every	  other	  day	  for	  30	  days.	  These	  results	  were	  replicated	  in	  a	  separate	  trial.	  The	  results	  
demonstrate	  that	  citrullination	  in	  peripheral	  immune	  cells	  increases	  during	  chronic	  EAE	  
suggesting	   that	   the	   increase	   in	   citrullination	   status	  observed	  previously	   in	  brain	   tissue	  
during	  chronic	  EAE	  could	  be	  due	  in	  part	  to	  the	  contribution	  of	  citrulline	  by	  immune	  cells	  
infiltrating	  the	  CNS.	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Fig.	  2.	  Citrulline	  status	  of	  spleen	  decreased	  following	  vitamin	  D	  treatment	  
(A)	   Immunoslot	   blot	   of	   protein	   extracted	   from	   pooled	   (n=2)	   spleen	   tissue	   samples	   of	  
naïve,	  EAE	  and	  1,25(OH)2D3	  treated	  EAE	  mice	  sacrificed	  at	  day	  14.	  Separate	  membranes	  
were	   probed	   for	   peptidyl	   citrulline	   and	   β	   actin.	   (B)	   Histogram	   of	   citrulline	   expression	  
normalized	  to	  β	  actin	  showing	  an	  increase	  in	  peptidyl	  citrulline	  in	  the	  spleen	  during	  EAE	  
that	  was	  attenuated	  by	  1,25(OH)2D3	  treatment.	  These	  results	  are	  representative	  of	  two	  
immunoslot	  blot	  experiments.	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MOG	  Stimulation	  Does	  Not	  Directly	  Affect	  PAD	  Gene	  Expression	  in	  Splenocytes	  
To	   understand	   whether	   the	   increase	   in	   PAD	   expression	   observed	   in	   the	   brain	  
was	   result	   of	   neural	   antigen	   induced	   PAD	   expression	   of	   invading	   peripheral	   immune	  
cells,	   we	   incubated	   splenocytes	   isolated	   from	   naïve,	   chronic	   EAE	   and	   chronic	   EAE-­‐
1,25(OH)2D3-­‐treated	   animals	   with	   10	   µg/ml	   of	   MOGp35-­‐55	   peptide	   for	   48	   hr.	   The	  
relative	   difference	   in	   PAD2	   and	   PAD4	   gene	   expression	   between	   splenocytes	   of	   naïve,	  
chronic	  EAE	  and	  1,25(OH)2D3	  observed	  in	  vivo	  (Fig.	  1C,F)	  are	  conserved	  during	  the	  48	  hr	  
ex	   vivo	   incubation.	   Incubation	   with	  MOG	   does	   not	   cause	   a	   significant	   change	   in	   the	  
expression	  of	  either	  PAD2	  (Fig.	  3A,B,C)	  or	  PAD4	  (Fig.	  3D,E,F)	  in	  splenocytes	  of	  any	  group.	  
These	  results	  demonstrate	  that	  neural	  antigen	  stimulation	  does	  not	  directly	  affect	  PAD	  
gene	  expression	  in	  peripheral	  immune	  cells.	  	  
	   	  
20	  
	  
Fig.	  3.	  Expression	  of	  PADs	  in	  splenocytes	  following	  MOG	  stimulation	  
(A-­‐C)	  PAD2	  expression	   in	   splenocytes	   isolated	  and	  pooled	   from	  naïve	   (A),	   EAE	   (B)	  and	  
1,25(OH)2D3	  treated	  EAE	  mice	  (C)	  following	  72	  hr	  stimulation	  with	  0	  or	  10	  µg/ml	  of	  the	  
MOGp35-­‐55	   antigen.	   (D-­‐F)	   PAD4	   expression	   in	   splenocytes	   isolated	   and	   pooled	   from	  
naïve	  (D),	  EAE	  (E)	  and	  1,25(OH)2D3	  treated	  EAE	  mice	  (F)	  following	  72	  hr	  stimulation	  with	  
0	  or	  10	  µg/ml	  of	  the	  MOGp35-­‐55	  antigen.	  In	  all	  assays,	  n=3. 
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Vitamin	  D	  Does	  Not	  Affect	  Splenocyte	  Viability	  in	  EAE	  
To	  confirm	  that	  the	  splenocytes	  isolated	  from	  each	  group	  were	  auto-­‐reactive	  to	  
the	  MOGp35-­‐55	   peptide	   of	   the	   ex	   vivo	   experiments,	  we	   assayed	   the	   viability	   of	   each	  
group	   following	   incubation	  with	   the	  peptide.	   Incubation	  with	   increasing	  concentration	  
of	  MOGp35-­‐55	  from	  0	  to	  10	  µg/ml	  exerted	  no	  observable	  effect	  on	  splenocyte	  viability	  
isolated	   from	   naïve	   animals	   (Fig.	   3A),	   but	   increased	   viability	   in	   a	   dose-­‐dependent	  
manner	  of	  both	  chronic	  EAE	   (Fig	  3B,	  p<0.0001,	  n=3)	  and	  1,25(OH)2D3-­‐treated	  chronic	  
EAE	   animals	   (Fig	   3C,	   p<0.001,	   n=3)	   indicating	   that	   only	   EAE	   spleens	   contained	   a	  
sufficient	   neural	   antigen	   reactive	   T	   cells	   reactive	   population.	   In	   vivo	   1,25(OH)2D3	  
treatment	  did	  not	  exert	  an	  effect	  on	  splenocyte	  viability	  following	  ex	  vivo	  neural	  antigen	  
stimulation.	   	   In	   vitro	   treatment	  of	   spleen	  cells	   isolated	   from	  EAE	  mice	  with	   increasing	  




Fig.	  4.	  Ex	  vivo	  and	  in	  vitro	  splenocyte	  viability	  
(A-­‐C)	  WST-­‐1	  assay	  of	  splenocytes	  isolated	  and	  pooled	  from	  naïve	  mice	  (A),	  EAE	  mice	  (B,	  
p<0.0001)	  and	  1,25(OH)2D3	  treated	  EAE	  mice	  (C,	  p<0.001)	  were	  stimulated	  with	  0,	  2.5,	  
5,	   or	   10	   µg/ml	   of	   the	  MOGp35-­‐55	   antigen	   for	   96hr.	   (D)	  WST-­‐1	   assay	   of	   splenocytes	  
isolated	  and	  pooled	  from	  EAE	  mice	  stimulated	  with	  0	  (-­‐)	  or	  10	  (+)	  µg/ml	  of	  the	  MOGp35-­‐
55	  antigen	  and	  treated	  with	  either	  5,	  10,	  25,	  50,	  100	  or	  250	  nM	  1,25(OH)2D3	  for	  96hr	  
(p=not	  significant).	  In	  all	  assays,	  n=3.	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Vitamin	  D	  Inhibits	  Viability	  of	  Macrophages	  and	  T	  Cells	  In	  Vitro	  
To	   study	   the	  effect	  of	   vitamin	  D	  on	  viability	  of	   specific	  peripheral	   immune	   cell	  
types,	   we	   performed	   a	   WST-­‐1	   assay	   of	   T	   cells	   and	   RAW	   cells	   in	   the	   presence	   of	  
increasing	   doses	   of	   1,25(OH)2D3	   in	   vitro.	   T	   cell	   viability	   is	   increased	   up	   to	   2.76-­‐fold	  
during	  96	  hr	  incubation	  in	  a	  dose	  dependent	  manner	  by	  lectin	  Con-­‐A	  from	  0	  to	  5ng/ml	  
(Fig.	  5A,	  p<0.05,	  n=3).	  Co-­‐treatment	  of	  T	  cells	  with	  2.5	  ng/mL	  Con-­‐A	  and	  an	   increasing	  
dose	   of	   1,25(OH)2D3	   from	   10	   to	   100	   nM	   drastically	   decreased	   T	   cell	   viability	   to	  
undetectable	  levels	  at	  50	  and	  100	  nM	  (Fig.	  5B,	  p<0.05,	  n=3).	  RAW	  cell	  stimulation	  with	  
increasing	  dose	  of	   Lipopolysaccharide	   (LPS)	   from	  0	   to	   1	  µg/ml	   slightly	   increased	  RAW	  
cell	  viability	  up	  to	  33%	  (Fig.	  5C,	  p<0.01,	  n=3).	  Incubation	  of	  RAW	  cells	  with	  1µg/mL	  LPS	  
with	   an	   increasing	   dose	   of	   1,25(OH)2D3	   from	   10	   to	   100	   nM	   decreased	   RAW	   cell	  




Fig.	  5.	  T	  cell	  and	  RAW	  cell	  proliferation	  decreased	  by	  vitamin	  D	  
(A)	  WST-­‐1	  assay	  of	  T	  cells	  treated	  with	  0,	  1,	  2.5	  or	  5	  ng/ml	  Con	  A	  for	  96hr	  (p<0.05).	  (B)	  
WST-­‐1	   assay	   of	   T	   cells	   treated	  with	   5	   ng/ml	   Con	   A	   and	   either	   10,	   25,	   50	   or	   100	   nM	  
1,25(OH)2D3	   for	   96	  hr	   (p<0.05).	   (C)	   RAW	  macrophage	   cells	   stimulated	  with	   0,	   .5	   or	   1	  
µg/ml	  LPS	  for	  96hr	  (p<0.01).	  (D)	  WST-­‐1	  assay	  of	  RAW	  macrophage	  cells	  stimulated	  with	  
1	  µg/ml	  LPS	  in	  the	  presence	  of	  either	  10,	  25	  or	  100	  nM	  1,25(OH)2D3	  for	  96hr	  (p<0.05).	  
In	  all	  assays,	  n=3. 
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Vitamin	  D	  Inhibits	  PAD-­‐Inducing	  Cytokine	  Production	  From	  Infiltrating	  Immune	  Cells	  	  
To	  understand	   the	   role	  of	   cytokines	   released	  by	   infiltrating	  peripheral	   immune	  
cells	  on	  the	  expression	  of	  PADs	  in	  brain	  tissue,	  we	  examined	  how	  supernatants	  collected	  
from	  spleen	  cell	  cultures	  affected	  expression	  of	  the	  two	  genes	  within	  the	  brain	  in	  vitro.	  
Naïve	  mixed	   cell	   brain	   cultures	  were	   incubated	   in	  media	   containing	   10%	   supernatant	  
collected	   at	   hour	   72	   from	   ex	   vivo	   spleen	   cell	   cultures	   of	   either	   naïve,	   chronic	   EAE	   or	  
1,25(OH)2D3-­‐treated	   chronic	   EAE	   mice.	   Supernatants	   from	   chronic	   EAE	   spleen	   were	  
able	   to	   increase	   the	  expression	  of	   PAD2	  and	  PAD4	   in	   the	  naïve	  brain	  by	  3.4-­‐fold	   (Fig.	  
6A,B,	  p<0.01,	  n=3)	  and	  1.7-­‐fold	  (Fig	  6C,D,	  p=not	  significant,	  n=3)	  respectively,	  compared	  
to	  supernatants	  collected	  from	  naïve	  spleen.	  The	  supernatant	  from	  splenocyte	  cultures	  
of	  1,25(OH)2D3-­‐treated	  chronic	  EAE	  animals	  were	  less	  potent	  at	  inducing	  expression	  of	  
PADs,	   increasing	   PAD2	   by	   2-­‐fold	   (Fig.	   6A)	   and	   PAD4	   by	   1.4-­‐fold	   (Fig.	   6C).	   These	   fold	  
changes	   are	   41%	   and	   23%	   less	   than	   the	   fold	   changes	   induced	   by	   supernatants	   from	  
spleen	  cultures	  of	  chronic	  EAE	  animals	  not	   treated	  with	  1,25(OH)2D3.	  Addition	  of	  100	  
nM	   1,25(OH)2D3	   to	   the	   mixed	   brain	   cell	   culture	   containing	   chronic	   EAE	   spleen	  
supernatant	  reduced	  PAD2	  expression	  by	  13%	  (Fig.	  6B)	  and	  PAD4	  expression	  48%	  (Fig.	  




Fig.	  6.	  Splenocyte	  induced	  PAD	  expression	  in	  mixed	  brain	  cell	  culture	  
Supernatants	  were	  collected	  after	  72	  hr	  from	  ex	  vivo	  stimulated	  splenocyte	  cultures	  of	  
naïve,	  EAE	  and	  1,25(OH)2D3	  treated	  EAE	  mice	  to	  determine	  the	  effect	  of	  cytokines	  on	  
the	  expression	  of	  PAD2	  (A,B)	  and	  PAD4	  (C,D)	   in	  mixed	  brain	  cell	  culture.	  Expression	  of	  
PAD2	   (A,	   p<0.01)	   and	   PAD4	   (C)	   in	   mixed	   brain	   cell	   cultured	   for	   48hr	   with	   10%	  
supernatants	  from	  splenocyte	  cultures	  of	  either	  naïve,	  EAE	  or	  1,25(OH)2D3	  treated	  EAE	  
mice.	  Expression	  of	  PAD2	  (B,	  p<0.01)	  and	  PAD4	  (D)	  in	  naïve	  mixed	  brain	  cell	  cultured	  for	  
48	  hr	  with	  either	  10%	  supernatant	  from	  naïve	  splenocyte	  culture,	  10%	  supernatant	  from	  
EAE	   splenocyte	   culture	   or	   10%	   supernatant	   from	  EAE	   splenocyte	   culture	   and	   100	   nM	  
1,25(OH)2D3	  added	  directly	  to	  the	  mixed	  brain	  cell	  culture.	  In	  all	  assays,	  n=3.	  
27	  
IFNɣ	  Induces	  PAD	  Expression	  in	  the	  Naïve	  Brain	  
To	  assay	  which	   cytokines	  might	  be	   responsible	   for	   the	   increased	  expression	  of	  
PADs	   observed	   in	   the	   brain	   during	   culture	   with	   splenocyte	   culture	   supernatants,	   we	  
treated	  mixed	  cell	  brain	  cultures	  with	  IL-­‐6,	  IL-­‐17	  and	  IFNɣ	  to	  measure	  expression	  of	  PAD2	  
(Fig.	   7A,B,C)	   and	   PAD4	   (Fig.	   7D,E,F).	  Mixed	   brain	   cell	   cultures	  were	   stimulated	  with	   1	  
µg/ml	   LPS	   and	   1	  mM	  ATP	   for	   46	   and	   6	   hr	   during	   48	   hr	   treatment	  with	   IL-­‐17	   or	   IFNɣ.	  
Treatment	  of	  stimulated	  cells	  with	  2	  ng/ml	  IL-­‐17	  had	  an	  insignificant	  effect	  on	  PAD2	  (Fig.	  
7A)	   and	   PAD4	   (Fig.	   7D)	   gene	   expression	   with	   and	   without	   co-­‐treatment	   of	   100	   nM	  
1,25(OH)2D3.	  In	  contrast,	  treatment	  of	  stimulated	  cells	  with	  4	  ng/ml	  IFNɣ	  induced	  PAD2	  
expression	  2.2-­‐fold	  (Fig.	  7B,	  p<0.01,	  n=3)	  and	  PAD4	  expression	  1.6-­‐fold	  (Fig.	  7E,	  p<0.01,	  
n=3)	  compared	  to	  stimulated	  control.	  Co-­‐treatment	  of	   IFNɣ	  with	  100	  nM	  1,25(OH)2D3	  
decreased	  PAD2	  expression	  72%	  (Fig.	  7B,	  p<0.01,	  n=3)	  and	  decreased	  PAD4	  expression	  
52%	   (Fig.	   7E,	   p<0.05,	   n=3),	   repressing	   expression	   of	   each	   gene	   below	   that	   of	   the	  
stimulated	  control.	  	  
48	   hr	   treatment	   of	   naïve	  mixed	   brain	   cell	   culture	  with	   2.5	   ng/ml	   recombinant	  
mouse	  IL-­‐6	  resulted	  in	  a	  1.2-­‐fold	  and	  2.0-­‐fold	  increase	  in	  the	  expression	  of	  PAD2	  (Fig.	  7C,	  
p=not	   significant,	   n=3)	   and	   PAD4	   (Fig.	   7F,	   p<0.01,	   n=3),	   respectively.	   However,	   this	  
induction	  was	  not	  affected	  significantly	  during	  co-­‐treatment	  with	  100	  nM	  1,25(OH)2D3.	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Fig.	  7.	  PAD	  expression	  in	  mixed	  brain	  cell	  culture	  in	  presence	  of	  IL-­‐17	  ,	  IFNɣ	  and	  IL-­‐6	  
Expression	  of	  PAD2	  (A-­‐C)	  and	  PAD4	  (D-­‐F)	  in	  48	  hr	  naïve	  mixed	  brain	  cell	  cultures.	  (A	  &	  D)	  
Treatment	  with	  1	  µg/ml	  LPS	  and	  1	  mM	  ATP	  at	  hour	  2	  and	  42,	  respectively,	  with	  0	  or	  2	  
ng/ml	  IL-­‐17	  and	  0	  or	  100	  nM	  1,25(OH)2D3	  (p=not	  significant).	  (B	  &	  E)	  Treatment	  with	  1	  
µg/ml	  LPS	  and	  1	  mM	  ATP	  at	  hour	  2	  and	  42,	  respectively,	  with	  0	  or	  4	  ng/ml	  IFNɣ	  and	  0	  or	  
100	  nM	  1,25(OH)2D3.	  Induction	  of	  PAD2	  (B,	  p<0.01)	  and	  PAD4	  (E,	  p=not	  significant)	  by	  
IFNɣ.	   Significant	   inhibition	   of	   IFNɣ	   induction	   by	   1,25(OH)2D3	   in	   PAD2	   expression	   (B,	  
p<0.01)	  and	  PAD4	  expression	  (E,	  p<0.05).	  (C	  &	  F)	  Treatment	  with	  0	  or	  2.5	  ng/ml	  IL-­‐6	  and	  
0	  or	  100	  nM	  1,25(OH)2D3.	  Significant	  induction	  of	  PAD4	  expression	  by	  IL-­‐6	  (F,	  p=<0.01).	  
In	  all	  assays,	  n=3.	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1,25(OH)2D3	  Directly	  Inhibits	  PAD2	  and	  PAD4	  Expression	  in	  the	  Brain	  	  
To	  understand	  the	  epigenetic	   role	  of	  vitamin	  D	  on	  the	  expression	  of	  PAD2	  and	  
PAD4	  in	  the	  brain,	  we	  examined	  the	  direct	  role	  of	  the	  1,25(OH)2D3	  on	  the	  expression	  of	  
the	  two	  genes	  in	  the	  naïve	  mixed	  brain	  cell	  culture.	  48	  hr	  treatment	  of	  mixed	  brain	  cell	  
culture	  with	  100nM	  1,25(OH)2D3	   reduces	  expression	  of	  PAD2	  expression	  by	  57%	   (Fig.	  
8A,	  p<0.01,	  n=4)	  and	  PAD4	  by	  47%	  (Fig.	  8B,	  p<0.05,n=4).	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Fig.	  8.	  Vitamin	  D	  inhibits	  PAD	  expression	  in	  mixed	  brain	  cell	  culture	  
(A)	   Expression	   of	   PAD2	   in	   48	   hr	   mixed	   brain	   cell	   culture	   treated	   with	   0	   or	   100	   nM	  
1,25(OH)2D3	   (p<0.01,	   n=4).	   (B)	   Expression	   of	   PAD4	   in	   48	   hr	   mixed	   brain	   cell	   culture	  





Relevance	  of	  Findings	  
MS	   is	   a	   disorder	   heterogeneous	   in	   clinical	   presentation,	   pathological	  
mechanisms	  and	  etiology.	  In	  this	  study	  we	  have	  demonstrated	  a	  link	  between	  a	  known	  
risk	  factor	  for	  developing	  the	  disease	  and	  a	  biochemical	  pathway	  at	  the	  intersection	  of	  
myelin	   destabilization	   and	   auto-­‐inflammation.	   Here	   we	   show	   vitamin	   D	   to	   inhibit	  
expression	   of	   PAD2	   AND	   PAD4	   in	   the	   CNS	   during	   EAE.	   A	   consensus	   on	   the	   role	   of	  
hypercitrullinated	   proteins	   in	   the	   pathophysiology	   of	   MS	   has	   yet	   to	   be	   reached,	   but	  
must	   lie	  somewhere	  on	  a	  continuum	  between	  irrelevant	  and	  causative.	   In	  favor	  of	  the	  
former,	  previous	  work	  has	  demonstrated	  citrullinated	  MOG	  antigen	  to	  be	  insufficient	  for	  
disease	   induction	  during	   EAE	   (Carrillo-­‐vico	  et	   al.,	   2014)	   and	   knock	  down	  of	   PAD2,	   the	  
major	   contributor	   of	   citrullination,	   does	   not	   prevent	   EAE	   induction	   (Raijmakers	   et	   al.,	  
2006).	  However,	  over-­‐expression	  of	  PAD2	   is	   sufficient	   to	  cause	  hypercitrullination	  and	  
spontaneous	   demyelination	   in	   transgenic	  mice	   (Musse	   et	   al.,	   2008).	   No	   single	  model	  
reflects	   the	   heterogeneity	   of	   MS,	   but	   inhibition	   of	   PAD	   activity	   has	   recently	   been	  
demonstrated	   to	   attenuate	   symptoms	   across	   four	   independent	   animal	  models	   of	  MS,	  
including	  both	  EAE	  models	  as	  well	  as	   two	  models	   that	  do	  not	  begin	  with	   immune	  cell	  
infiltration	  of	   the	  CNS	  (Moscarello	  et	  al.,	  2013).	  These	  results	   imply	  PAD	  activity	   to	  be	  
conserved	   across	   various	   demyelinating	   processes	   involving	   both	   biochemical	  
perturbations	  of	  the	  myelin	  sheath	  and	  auto-­‐inflammatory	  mechanisms.	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Here	   we	   have	   demonstrated	   robust	   induction	   of	   PAD2	   and	   PAD4	   in	   the	   CNS	  
during	  EAE	  as	  is	  observed	  in	  MS.	  Previous	  studies	  have	  demonstrated	  PAD	  activity	  and	  
citrullination	   in	  the	  brain	  to	   increase	  along	  with	  PAD	  mRNA	  levels	   indicating	  PAD	  gene	  
expression	   to	   reflect	   citrullination	   status	   of	   the	   brain	   (Musse	   et	   al.,	   2008).	   To	   our	  
knowledge,	   this	   is	   the	   first	   study	  to	  show	  vitamin	  D	  to	   inhibit	  expression	  of	  PAD2	  and	  
PAD4	   in	   the	  CNS	  during	  EAE.	  This	   finding	  greatly	  expands	   the	   role	  of	  vitamin	  D	   in	   the	  
pathogenesis	   of	   EAE/MS	   outside	   of	   its	   role	   as	   an	   immunomodulator.	   Future	   studies	  
need	  to	  be	  performed	  to	  confirm	  that	  the	  decrease	  in	  PAD	  expression	  during	  vitamin	  D	  
treatment	   corresponds	   to	   a	   reduction	   in	   the	   citrullination	   status	   as	   the	   process	   of	  
deimination	   is	   regulated	  at	  multiple	   levels	   outside	  of	  mRNA	  expression	   assessed	  here	  
(Ve,	  Serre,	  and	  Simon,	  2010).	  	  
	   	  
Multiple	  Inhibitory	  Roles	  for	  Vitamin	  D	  in	  Expression	  of	  PAD	  2	  and	  4	  	  
Both	   immune	   and	   neural	   cells	   express	   PAD2	   and	   PAD4,	   so	   the	   gene	   induction	  
observed	  in	  brain	  and	  spine	  tissue	  during	  EAE	  could	  be	  result	  of	  PAD	  expression	  within	  
immune	  cells	  infiltrating	  the	  CNS.	  In	  mice,	  expression	  of	  PAD2	  is	  two-­‐fold	  higher	  in	  the	  
brain	  than	  spleen,	  but	  bone	  marrow	  derived	  mast	  cells	  express	  PAD2	  about	  twenty-­‐fold	  
greater	  than	  brain	  tissue	  (Arandjelovic	  et	  al.,	  2014).	  Mast	  cells	  localize	  to	  active	  lesions	  
and	   regions	   of	   perivascular	   infiltration	   in	   the	   brain	   during	   MS	   (Toms,	   Weiner,	   and	  
Johnson,	  1990),	  indicating	  that	  the	  increase	  in	  PAD	  expression	  we	  observed	  in	  the	  brain	  
could	  be	  due	  in	  part	  to	  PAD	  mRNA	  produced	  by	  mast	  cells.	  Relevant	  to	  the	  Th1	  model	  of	  
MS,	  macrophages	   and	  monocytes	   have	   been	   demonstrated	   to	   increase	   expression	   of	  
33	  
PAD2	   and	   PAD4	   during	   contact	   and	   cytokine	   stimulation	   by	   activated	   T	   cells	   (Ferrari-­‐
lacraz	  et	  al.,	  2012)	  as	  would	  be	  expected	  in	  areas	  of	  inflamed	  neural	  tissue	  in	  MS.	  	  
Our	   viability	   assays	   demonstrate	   vitamin	   D	   to	   inhibit	   T	   cell	   and	   macrophage	  
viability	   in	   vitro	   but	   the	   effect	   of	   vitamin	   D	   on	   whole	   spleen	   cell	   culture	   was	   much	  
reduced.	  These	   results	   suggest	  neural	  antigen	  stimulated	  T	  cells	   to	  be	   resistant	   to	   the	  
viability	   modulation	   by	   vitamin	   D	   or	   that	   other	   splenocytes	   contribute	   to	   T	   cell	   and	  
macrophage	  viability	  during	  vitamin	  D	  treatment	  in	  the	  whole	  spleen	  culture.	  Previously,	  
we	   have	   shown	   1,25(OH)2D3	   in	   vitro	   treatment	   to	   profoundly	   inhibit	   splenocyte	  
proliferation	  when	  measured	  using	  thymidine	  uptake	  (Bright	  et	  al.,	  2006).	  The	  seemingly	  
conflicting	  results	  from	  these	  two	  methods	  indicate	  vitamin	  D	  to	  play	  a	  role	  modulating	  
splenocyte	  replication	  but	  not	  viability	  during	  96	  hr	  treatment	  with	  vitamin	  D.	  	  	  
These	   results	   in	   conjunction	   with	   the	   observed	   reduction	   in	   brain	   tissue	   PAD	  
expression	   following	  vitamin	  D	   treatment	  suggest	  a	   few	  possible	  mechanistic	   roles	   for	  
vitamin	  D	  in	  the	  pathogenesis	  of	  MS	  (Fig.	  9);	  vitamin	  D	  decreases	  PAD	  expression	  in	  the	  
brain	  by	  limiting	  the	  number	  of	  infiltrating	  T	  cell	  and	  macrophages;	  vitamin	  D	  attenuates	  
peripheral	   immune	  cell	  production	  of	  PAD	   inducing	  cytokine	  production	  on	  the	  neural	  
tissue;	  and	  vitamin	  D	  attenuates	  neural	  tissue	  PAD	  expression	  in	  response	  to	  infiltrating	  
cells.	  Vitamin	  D’s	  direct	   inhibition	  of	  PAD	  expression	   in	   infiltrating	   immune	  cells	   is	   less	  
likely	   since	   the	   compound	   induces	   PAD	   expression	   in	   RAW	  macrophages	   (results	   not	  
shown)	  and	  it	  is	  not	  expressed	  in	  appreciable	  amounts	  by	  T	  cells.	  	  
Interestingly,	  PAD2	  is	  expressed	  fifty	  fold	  higher	  in	  smooth	  muscle	  as	  compared	  
to	  whole	  brain	  tissue	  homogenate	  (Arandjelovic	  et	  al.,	  2014).	  There	  is	   little	  agreement	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about	   what	   neural	   cell	   types	   contribute	   most	   to	   the	   increase	   in	   PAD	   expression	  
observed	   during	   MS	   with	   oligodendrocytes	   and	   astrocytes	   implicated	   to	   play	   a	   role	  
(Vossenaar	   et	   al.,	   2003).	   The	   potential	   for	   neural	   vasculature	   to	   contribute	   to	   PAD	  
expansion	   is	   especially	   intriguing	   given	   heavy	   citrullination	   status	   of	   MBP	   in	   active	  
lesions	  often	  located	  in	  perivascular	  regions.	  Future	  studies	  are	  required	  to	  investigate	  
the	   relevance	   of	   vascular	   smooth	  muscle	   contribution	   to	   PAD	   expression	   in	   the	   brain	  
during	  EAE.	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Fig.	  9.	  Multiple	  roles	  of	  vitamin	  D	  inhibiting	  PAD	  expression	  in	  the	  brain	  
A	  summary	  of	  vitamin	  D	  mediated	  inhibition	  of	  PAD	  expression	  in	  the	  brain.	  Vitamin	  D	  -­‐
inhibits	   proliferation	   of	   T	   and	   RAW	   cells.	   Vitamin	   D	   inhibits	   production	   of	   PAD2	   and	  
PAD4	   inducing	   cytokines,	   notably	   IFNɣ.	   Vitamin	  D	   directly	   inhibits	   expression	   of	   PAD2	  
and	  PAD4	   in	   the	  brain,	   alone	  and	  during	  peripheral	   immune	  cell	   cytokine	   stimulation.	  
Citrullinated	  MBP,	   primarily	  mediated	   by	   PAD2,	   increases	   inflammation	   by	   both	   local	  
glial	   cells	   and	   infiltrating	   peripheral	   immune	   cells.	   Citrullinated	   H3	   is	   associated	   with	  
oligodendrocyte	  apoptosis.	  Both	   inflammation	  and	  oligodendrocyte	  apoptosis	   result	   in	  
demyelination.	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The	   expression	   of	   PAD	   in	   mixed	   brain	   cell	   culture	   in	   response	   to	   splenocyte	  
supernatants	  demonstrate	  immune	  cell	  secreted	  cytokines	  to	  induce	  PAD	  expression	  in	  
the	  brain.	  These	  results	  support	  the	  latter	  two	  mechanistic	  roles	  for	  vitamin	  D	  mediated	  
inhibition	  of	  PAD	  expression	  introduced	  above;	  showing	  vitamin	  D	  to	  reduce	  the	  ability	  
of	   splenocytes	   to	   induce	   PAD	   expression	   in	   the	   brain	   and	   vitamin	   D	   to	   inhibit	   PAD	  
induction	   in	   the	   brain	   in	   response	   to	   secreted	   cytokines.	   Mixed	   brain	   cell	   cultures	  
incubated	   with	   splenocyte	   supernatants	   demonstrate	   neural	   antigen	   induced	  
splenocytes	   of	   EAE	  mice	   to	   release	   a	   cytokine	   profile	   more	   capable	   of	   inducing	   PAD	  
expression	   in	   the	   naïve	   brain	   as	   compared	   to	   supernatant	   from	   splenocytes	   isolated	  
from	  naïve	  or	  vitamin	  D	  treated	  EAE	  mice.	  PAD	  expression	  by	  neural	  tissue	  in	  response	  
to	   peripheral	   immune	   cell	   cytokine	   profiles	   could	   represent	   a	   negative	   feedback	   loop	  
that	  becomes	  over-­‐activated	  during	  MS	  pathology.	  Previous	  studies	  have	  demonstrated	  
citrullination	  to	  alter	  immunomodulatory	  functions	  of	  several	  cytokines	  including	  TNFα	  
(Moelants	   et	   al.,	   2013)	   and	   IL-­‐8	   (Proost	   et	   al.,	   2008).	   Continued	   stimulation	   of	   PAD	  
expression	  by	  neural	  tissue	  in	  response	  to	  infiltrated	  immune	  cells	  in	  combination	  with	  
the	  low	  specificity	  of	  PAD2	  and	  PAD4	  might	  represent	  a	  pathway	  by	  which	  citrullination	  
of	  myelin	  proteins	  accumulates	  during	  MS.	  	  
	  
Implications	  of	  IFNɣ	  and	  IL-­‐6	  As	  Inducers	  of	  PAD	  Expression	  
Our	   results	   show	   both	   IL-­‐6	   and	   IFNɣ	   to	   be	   inducers	   of	   PAD	   expression.	   IL-­‐6	   is	  
involved	   in	   both	   the	   autoimmune	   response	   by	   invading	   peripheral	   immune	   cells	   and	  
acts	   as	   an	   important	   mediator	   of	   neural	   inflammation	   independent	   of	   infiltration.	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Previous	   studies	   have	   shown	   IL-­‐6	   production	   by	   dendritic	   cells	   important	   to	   T	   cell	  
priming	   during	   EAE	   induction	   (Leech	   et	   al.	   2014).	   Venous	   insufficiency	   has	   been	  
implicated	   in	  MS	  and	   IL-­‐6	  blockade	  attenuates	  brain	   inflammation	  during	  hypoxia	   (SH	  
Yang	  et	  al.	  2013).	  IL-­‐6	  is	  known	  to	  signal	  gene	  induction	  through	  the	  SP1	  transcriptional	  
factor	  (Gene	  et	  al.,	  2008)	  and	  PAD2	  expression	  has	  been	  shown	  to	  be	  modulated	  by	  four	  
SP1	   binding	   sites	   (Serre	   et	   al.,	   2005),	   which	   also	   lie	   in	   the	   vicinity	   of	   PAD4	   on	  
chromosome	   one.	   Our	   results	   demonstrate	   IL-­‐6	   to	   induce	   PAD4	   but	   not	   PAD2.	  
Interestingly,	   vitamin	   D	   had	   no	   inhibitory	   effect	   on	   this	   induction.	   PAD4	   contains	   a	  
nuclear	  localization	  sequence	  where	  as	  PAD2	  does	  not.	  The	  citrullination	  of	  histone	  H3	  
by	   PAD4	   following	   TNFα	   stimulation	   is	   associated	   with	   oligodendrocyte	   apoptosis	  
(Mastronardi	   et	   al.,	   2006).	   Our	   results	   outline	   a	   possible	   mechanistic	   role	   for	   IL-­‐6	   to	  
potentiate	  neurodegeneration	  via	  induction	  of	  PAD4.	  	  
Here	  we	  show	  IFNɣ	  to	  increase	  expression	  of	  both	  PAD2	  and	  PAD4,	  identifying	  a	  
novel	   role	   for	   the	   IFNɣ	   /	   IL-­‐12	   axis	   in	   the	   pathogenesis	   of	   MS.	   Previously,	   we	   have	  
demonstrated	  vitamin	  D	  to	  attenuate	  IFNɣ	  production	  by	  Th1	  cells	  (Bright	  et	  al.,	  2006).	  
Here	  we	  also	  show	  vitamin	  D	  to	  inhibit	  PAD	  induction	  in	  the	  brain	  in	  response	  to	  IFNɣ.	  
Since	  citrullination	  of	  myelin	  sheath	  proteins	  auto-­‐reacts	  with	  a	  broader	  repertoire	  of	  T	  
cells,	  these	  results	  imply	  that	  in	  the	  absence	  of	  vitamin	  D,	  T	  cell	  mediated	  induction	  of	  
PAD	   expression	   in	   the	   brain	   might	   predispose	   the	   myelin	   sheath	   to	   further	   auto-­‐
aggression	  and	  a	  cycle	  of	  inflammation.	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Concluding	  Remarks	  and	  Future	  Directions	  	  
Some	   consider	   MS	   to	   be	   a	   collection	   of	   disorders	   that	   begins	   with	  
oligodendrocyte	   apoptosis	   before	   invasion	  of	   the	  CNS	  by	   the	  peripheral	   immune	   cells	  
(Barnett	   and	   Prineas	   2006).	   There	   are	   several	   transgenic	   models	   that	   demonstrate	  
biochemical	  perturbations	  of	  the	  myelin	  sheath	  to	  play	  an	  etiologic	  role	  in	  MS.	  Increased	  
PAD	   expression	   and	   hypercitrullination	   precede	   symptoms	   in	   the	   ND4	   model,	   which	  
involves	  destabilization	  of	  the	  myelin	  sheath	  by	  over	  expression	  of	  the	  DM20	  proteolipid	  
(F	   G	  Mastronardi	   et	   al.,	   1993).	   And	   PAD2	   over-­‐expression	   in	   the	   CNS	   is	   sufficient	   to	  
cause	   spontaneous	   demyelination	   (Musse	   et	   al.	   2008).	   The	   role	   of	   protein	  
hypercitrullination	   across	   demyelinating	   models	   is	   mounting.	   Here	   we	   have	   shown	  
vitamin	   D	   to	   inhibit	   immune	   cell	   induction	   of	   PADs	   in	   the	   brain	   and	   demonstrated	   a	  
direct	  role	  for	  vitamin	  D	  to	  attenuate	  endogenous	  PAD	  expression	  in	  the	  brain	  without	  
invading	  immune	  cells.	  	  
Regardless	   as	   to	   whether	   hypercitrullination	   is	   a	   causative	   factor,	   or	   simply	  
potentiates	   demyelination	   across	   various	   mechanisms,	   the	   relevance	   of	   vitamin	   D	  
deficiency	   to	   predispose	   enhanced	   PAD	   expression	   in	   the	   CNS	   needs	   investigating.	  
Specifically,	  does	  vitamin	  D	  modulate	  the	  methylation	  status	  of	  the	  PAD2	  promoter	  and	  
if	  so,	  can	  this	  imprinting	  be	  modulated	  in	  utero	  and	  early	  life?	  Vitamin	  D	  deficiency	  from	  
the	  time	  of	  conception	  to	  about	  twenty	  years	  old	  increases	  one’s	  risk	  for	  developing	  MS	  
(Pierrot-­‐deseilligny	  and	  Souberbielle	  2013).	  This	  time	  period	  is	  associated	  with	  the	  vast	  
majority	  of	  neurodevelopment	  and	  a	  reduction	  in	  the	  citrullination	  of	  MBP.	  However	  MS	  
adults	  have	  a	  citrullination	  status	  similar	  to	  that	  of	  early	  childhood	  (Wood	  et	  al.,	  1996).	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Perhaps	   vitamin	  D	   deficiency	   during	   this	   critical	   period	   allows	   for	   hypomethlyation	   of	  
the	   PAD2	   promoter	   predisposing	   the	   CNS	   to	   become	   hypercitrullinated	   from	   an	  





Multiple	   sclerosis	   (MS)	   is	   a	   disabling	   disorder	   that	   afflicts	   an	   estimated	   2.3	  
million	   people.	   The	   etiology	   of	   the	   disorder	   is	   poorly	   understood,	   but	   vitamin	   D	  
deficiency	   appears	   to	   increase	   risk	   of	   developing	   MS.	   The	   disorder	   involves	  
demyelination	  of	  the	  central	  nervous	  system	  (CNS)	  associated	  with	  peripheral	   immune	  
cells	  infiltrating	  the	  blood	  brain	  barrier	  and	  contributing	  to	  demyelination	  processes.	  In	  
addition,	   various	   biochemical	   perturbations	   to	   the	   myelin	   sheath	   including	  
posttranslational	  modifications	   and	  over	   expression	  of	   various	  proteolipids	   have	  been	  
demonstrated	   to	   trigger	  myelination	   apart	   from	   infiltrating	   immune	   cells.	   The	   diverse	  
pathophysiology	   of	  MS	   is	   represented	   in	   a	   variety	   of	   animal	   models	   that	   collectively	  
reflect	  the	  heterogeneity	  of	  disease	  mechanisms	  and	  clinical	  symptoms	  observed	  across	  
MS.	  Recently,	  the	  inhibition	  of	  protein	  arginine	  deiminase	  (PAD)	  family	  enzyme	  has	  been	  
shown	   to	   attenuate	   or	   entirely	   avoid	   disease	   progression	   in	   four	   independent	   animal	  
models	  of	  multiple	  sclerosis	  demonstrating	  the	  relevance	  of	  PAD	  activity	  across	  various	  
demyelination	   processes.	   PAD	   enzymes	   carry	   out	   a	   post-­‐translational	   modification	   of	  
arginine	  peptide	  residues	  to	  citrulline	  resulting	  in	  a	  loss	  of	  mass	  and	  positive	  charge	  to	  
each	   residue	   modified.	   PAD2	   and	   PAD4	   are	   over-­‐expressed	   during	   MS,	   but	   the	  




Using	   the	  experimental	  autoimmune	  encephalomyelitis	   (EAE)	  model	  of	  MS,	  we	  
demonstrate	  vitamin	  D	  to	  inhibit	  expression	  of	  PAD2	  and	  PAD4	  in	  CNS	  tissue	  during	  the	  
disorder.	  We	  demonstrate	   PADs	   induction	   in	   the	   brain	   by	   stimulation	  with	   peripheral	  
immune	   cell	   cytokine	   profile,	   but	   no	   change	   in	   PAD	   expression	   during	   neural	   antigen	  
stimulation	  of	  splenocytes.	  Specifically,	  we	  identify	  IFNɣ	  released	  by	  infiltrating	  T	  cells	  to	  
be	  an	  inducer	  of	  each	  gene	  and	  outline	  multiple	  modes	  by	  which	  vitamin	  D	  inhibits	  the	  
ability	  of	   invading	  immune	  cells	  to	   induce	  PAD	  expression	  in	  the	  brain.	   In	  addition,	  we	  
show	  vitamin	  D	  to	  exert	  a	  direct	  role	  inhibiting	  PAD	  expression	  within	  neural	  tissue.	  	  
	  
Implications	  and	  Further	  Directions	  
Our	   results	   imply	   that	   the	   vitamin	   D	   deficiency	   risk	   factor	   associated	  with	  MS	  
might	   predispose	   the	   CNS	   to	   over	   express	   PADs	   and	   potentiate	   demyelination	  
spontaneously,	   by	   environmental	   insult	   or	   during	   immune	   cell	   infiltration.	   Future	  
investigations	   should	   determine	   if	   vitamin	   D	   is	   responsible	   for	   modulating	   the	  
methylation	   status	   of	   the	   PAD2	   promoter	   region,	   which	   has	   previously	   been	  
demonstrated	   to	   be	   hypomethylated	   in	  MS	   patients.	   Identifying	   a	   direct,	  mechanistic	  
link	   between	   a	   well-­‐characterized	   environmental	   risk	   factor	   and	   biochemical	   process	  
involved	   in	   MS	   disease	   progression	   will	   enable	   a	   better	   understanding	   of	   the	  
pathogenesis	  of	  MS	  and	  other	  complex	  epigenetic	  disorders.	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APPENDIX:	  ADDITIONAL	  METHODS	  
	  
Within	  this	  appendix	  are	  additional	  methods	  I	  learned	  throughout	  the	  year	  in	  the	  
Dr.	   Bright’s	   laboratory.	   Some	  descriptions	   are	   expanded	  notes	   upon	  methods	   used	   in	  
the	   experiments	   of	   the	   thesis,	   while	   others	   include	  methods	   that	   never	   panned	   out.	  
Each	   involved	   troubleshooting,	   lending	   a	   variety	   of	   null	   results.	   The	   protocols	   and	  
selected	  results	  for	  some	  methods	  are	  included	  here	  as	  reference	  for	  future	  trials.	  A	  list	  
of	  the	  figures	  in	  this	  appendix	  are	  included	  below.	  
	  
	  
Fig.	  A1.	  Example	  of	  peptidyl	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  western	  blot	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  50	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  51	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  of	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  ELISA	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  of	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  Phosphatase	  ELISA	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  54	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  56	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  double	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  of	  mixed	  brain	  cell	  culture	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  57	  
Fig.	  A8.	  Example	  of	  flow	  cytometry	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  of	  DB29	  immortalized	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  59	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  A9.	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  61	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Cell	  Culture	  and	  Techniques	  
Neural	  Stem	  Cell	  Culture	  
Harvest	  brain	   from	  newborn	  mouse	  pup	  and	  homogenate	  without	   shearing	  by	  
pressing	  the	  brain	  between	  two	  frosted	  glass	  slides.	  Culture	  cells	  in	  neural	  basal	  medium	  
(NBM)	  containing	  10%	  FBS,	  20	  µl	  B27	  per	  ml	  NBM,	  and	  1	  ng/ml	  each	  of	  EGF	  and	  FGF	  for	  
about	  one	  week	  until	  neural	   spheres	  proliferate.	  Add	  additional	  medium	  during	   initial	  
culture	   if	  medium	  changes	  color	   from	  pink	   to	  yellow.	  Harvest	  cells	   into	  a	  conical	   tube	  
and	  allow	  neural	  spheres	  to	  settle	  to	  base	  of	  tube	  for	  5	  min.	  Remove	  media	  and	  other	  
mixed	  cells	  in	  supernatant.	  Do	  not	  centrifuge	  neural	  stem	  cell	  spheres.	  	  
	  
EOC20	  Cell	  Culture	  
Microglia	   cells	   cultured	   in	   DMEM	   with	   heat-­‐inactivated	   10%	   FBS	   and	   10%	  
LADMAC	  culture	  soup	  at	  high	  cell	  concentrations.	  EOC20	  culture	  takes	  weeks	  to	  become	  
confluent	  as	  compared	  to	  RAW	  macrophage	  culture.	  	  
	  
DB29	  Cell	  Culture	  
Immortalized	   human	   oligodendrocyte	   cell	   line	   cultured	   in	   DMEM	   with	   heat-­‐
inactivated	  10%	  FBS.	  Grow	  relatively	  quickly	  with	  diffuse	  projections.	  Must	  harvest	  by	  
trypsinizing	  cells	  from	  culture	  flask.	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Awaking	  &	  Freezing	  Cell	  Lines	  
Awaken	  cells	  as	  quickly	  as	  possible.	  Freeze	  cells	  slowly.	  To	  awaken:	  thaw	  cells	  in	  
the	   water	   bath	   quickly,	   suspend	   in	   PBS,	   spin	   down	   at	   1500	   rpm	   for	   5	   min,	   remove	  
supernatant	   and	   resuspend	   in	   fresh	  media.	   To	   freeze:	   collect	   cells	   and	   spin	   down	   in	  
vials,	  remove	  culture	  media	  from	  pellet,	  resuspend	  pellet	  in	  freezing	  media	  (70%	  culture	  
media,	  10%	  DMSO,	  20%	  FBJ),	  place	  vials	  into	  Nalgene	  freezing	  container	  and	  then	  move	  
to	  liquid	  nitrogen	  the	  following	  morning.	  	  
	  
Harvesting	  Cells	  with	  Trypsin	  
Remove	  media.	  Gently	  rinse	  cells	  with	  PBS.	  Add	  Trypsin	  solution	  for	  5	  min	  while	  
in	  37	  °C	   incubator.	  Check	  to	  see	  that	  all	  cells	  are	  detached	  using	  the	   light	  microscope.	  
Add	  media	  to	  neutralize	  the	  trypsin.	  Take	  a	  sample	  to	  count	  the	  cells	  if	  necessary.	  Spin	  
down	  cells	  at	  1500	  rpm	  for	  5	  min.	  Re-­‐suspend	  cell	  pellet	  in	  fresh	  media.	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Gene	  Detection	  Techniques	  
RNA	  Extraction	  
Spin	  down	  cells	  1500	  rpm	  for	  5	  min	  and	  remove	  medium.	  Rinse	  pellet	  with	  PBS	  
and	  spin	  down	  2000	  rpm	  for	  5	  min.	  Discard	  PBS	  and	  add	  500	  µl	  Trizol	  reagent.	  Vortex	  for	  
15	  sec	  or	  sonicate	  over	  ice	  if	  neural	  stem	  cells.	  Centrifuge	  for	  15	  min	  at	  12,000	  rcf.	  Add	  
200	  µl	  chloroform	  and	  vortex	  for	  15	  sec,	  then	  incubate	  at	  room	  temperature	  for	  3	  min.	  
Centrifuge	  for	  15	  min	  at	  12,000	  rcf.	  Transfer	  clear	  aqueous	  layer	  only	  into	  fresh	  epindorf	  
tubes	   containing	   500	   µl	   of	   2-­‐propanol.	   Incubate	   at	   room	   temperature	   for	   10	   min.	  
Centrifuge	  for	  10	  min	  at	  12,000	  rcf.	  Discard	  supernatant	  and	  add	  500	  µl	  of	  75%	  ethanol	  
to	  each	  and	  vortex.	  Centrifuge	  for	  5	  min	  at	  7,500	  rcf.	  Discard	  supernatant,	  invert	  and	  let	  
dry	  briefly.	  Add	  40	  µl	  of	  DPEC	  and	  then	  quantify	  before	  storing	  at	  -­‐80	  °C.	  	  
	  
Reverse	  Transcription	  Notes	  	  
When	  using	  the	  High	  Capacity	  Reverse	  Transcription	  kit	  (Applied	  Biosystems)	  use	  
4	  µl	  10x	  Reverse	  Transcriptase	  Buffer,	  1.6	  µl	  DNTPs,	  4	  µl	  random	  primers,	  2	  µl	  reverse	  
transcriptase	  per	  20	  µl	  total	  of	  sample	  to	  be	  reverse	  transcribed.	  RNA	  should	  be	  loaded	  
ideally	  100-­‐500	  ng	  per	  sample,	  though	  can	  be	  much	  lower	  if	  all	  are	  matched.	  Volume	  of	  
RNA	  should	  range	  2-­‐4	  µl	  per	  sample,	  allowing	  the	  remaining	  volume	  to	  be	  made	  up	  to	  




The	   volume	   of	   the	   reaction	   chamber	   well	   can	   usually	   be	   much	   lower	   than	  
suggested	   by	   Applied	   Biosystems	   if	   run	   for	   60	   cycles	   instead	   of	   the	   default	   40.	  
Saravanan’s	  protocol	  includes	  10.5	  µl	  of	  PCR	  master	  mix	  and	  2	  µl	  of	  cDNA,	  for	  a	  total	  of	  
~13	  µl	  per	  reaction	  well.	  Make	  master	  mix	  by	  adding	  6.25	  µl	  Quiagen	  sybgr	  master	  mix,	  
.5	  µl	  primer	  and	  3.75	  µl	  RNA-­‐ase	  free	  water.	  Add	  10.5	  µl	  PCR	  master	  mix	  per	  well	  and	  
then	  2	  µl	  of	  cDNA.	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Protein	  Detection	  Techniques	  
Protein	  Extraction	  
Create	  lysis	  solution	  using	  11	  ml	  1x	  RIPA	  lysis	  buffer,	  1	  ml	  .1%	  SDS,	  12.5	  µl	  each	  
of	  leupoprotein	  and	  apoprotein	  1000x,	  and	  125	  µl	  PMSF	  100x.	  Add	  20	  µl	  of	  lysis	  solution	  
to	  cell	  pellet	  and	  lyse	  on	  sonicator.	  Rock	  at	  4	  °C	  for	  1	  hr.	  Centrifuge	  at	  10,000	  rpm	  for	  10	  
min.	   Retain	   supernatant,	   which	   contains	   the	   soluble	   protein,	   and	   discard	   the	   pellet.	  
Load	  10	  µl	  each	  of	  samples	  and	  standards	  onto	  a	  96	  well	  plate.	  Mix	  BCA	  Protein	  Assay	  
solution	   (Thermo)	  5ml	  A	   to	  100	  µl	  B,	   then	  add	  200	  µl	  of	   solution	   to	  each	   sample	  and	  
dark	  incubate	  at	  room	  temperature	  for	  30	  min.	  Read	  and	  compare	  sample	  absorbance	  
to	  standard	  curve.	  	  
	  
Western	  Blot	  
Cast	  5ml	  mini	  resolving	  gel	  using	  1.6	  ml	  water,	  2.0	  ml	  30%	  acrylamide	  mix,	  1.3	  ml	  
1.5	  M	  Tris	  (pH	  8.8),	  50	  µl	  10%	  SDS,	  50	  µl	  10%	  ammonium	  persulfate,	  and	  2	  µl	  TEMED.	  
Allow	  to	  set	  before	  casting	  stacking	  gel.	  Cast	  2ml	  mini	  stacking	  gel	  using	  1.4	  ml	  water,	  
.33	   ml	   30%	   acrylamide	   mix,	   .13	   ml	   1.5	   M	   Tris	   (pH	   8.8),	   10	   µl	   10%	   SDS,	   10	   µl	   10%	  
ammonium	  persulfate,	   and	  1	  µl	   TEMED.	  Add	   comb	  and	  allow	   to	   set.	  Add	  equal	  µg	  of	  
protein	  between	  samples	   into	   loading	  buffer,	  boil	   for	  10	  min,	  spin	  down	  and	  load	  into	  
gel.	  Run	  gel	  at	  100	  mV.	  	  
Rinse	  a	  membrane	  in	  methanol	  for	  3	  min.	  Place	  three	  filter	  papers	  into	  transfer	  
apparatus	  and	  wet	  with	  transfer	  buffer,	  place	  membrane	  atop	  filter	  papers,	  remove	  gel	  
and	  place	  on	  membrane,	  then	  place	  two	  filter	  papers	  atop	  gel.	  Wet	  the	  entire	  stack	  with	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transfer	  buffer,	   removing	  any	  air	  bubbles	  by	  rolling	  a	  glass	  pipette	  over	   the	  stack.	  Dry	  
the	  area	  around	  the	  stack	  and	  then	  close	  apparatus.	  Run	  at	  100	  mA	  for	  90	  min.	  	  
Remove	  membrane	  and	  block	  in	  5%	  milk	  TBST	  for	  1	  hr	  at	  room	  temperature.	  Add	  
primary	  antibody	  in	  2.5%	  milk	  TBST	  overnight	  on	  rocker	  at	  4	  C.	  The	  following	  morning,	  
remove	  from	  refrigerator	  and	  rock	  at	  room	  temperature	  for	  1	  hr.	  Rinse	  in	  PBST	  3x	  at	  20	  
min	  each.	  Incubate	  with	  biotin	  conjugated	  secondary	  antibody	  in	  2.5%	  milk	  TBST	  for	  1	  hr	  
at	   room	   temperature.	   Rinse	   in	   PBST	   3x	   at	   20	  min	   each.	   Add	   2ml	   of	   each	   part	   of	   ECL	  
solution	  (Supersignal	  West	  Pico,	  Thermo)	  and	  rock	  at	  room	  temperature	  for	  5	  min	  and	  
then	  image	  as	  described	  in	  slot	  blot.	  Examples	  of	  trials	  are	  included	  (Fig.	  A1,2,3).	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Fig.	  A1.	  Example	  of	  peptidyl	  citrulline	  western	  blot	  	  
Western	   blot	   of	   brain	   protein	   extracts	   probed	   for	   peptidyl	   citrulline	   (1:500).	   The	  
antibody	  binds	  any	  proteins	  expressing	  citrulline	  resulting	  in	  smearing.	  The	  far	  left	  brain	  




Fig.	  A2.	  Example	  of	  beta	  actin	  and	  MOG	  western	  blot	  	  
Western	   blot	   of	   brain,	   spine	   and	   spleen	   protein	   extracts	   run	   in	   triplicate	   from	   left	   to	  




Fig.	  A3.	  Example	  of	  beta	  actin	  western	  blot	  	  
Western	   blot	   of	   brain,	   spine	   and	   spleen	   protein	   extracts	   run	   in	   triplicate	   from	   left	   to	  
right	  probed	  for	  beta	  actin.	  Beta	  actin	  was	  only	  detectable	   in	  the	  spleens	  on	  this	  trial.	  
52	  
Cytokine	  ELISA	  
The	   effect	   of	   neural	   antigen	   stimulation	   and	   1,25(OH)2D3	   on	   IFNɣ	   and	   IL-­‐12	  
secretion	   in	   whole-­‐spleen	   cell	   culture	   was	   determined	   by	   ELISA.	   Spleen	   cell	   cultures	  
were	  created	  from	  pooled	  spleen	  tissue	  samples	  isolated	  at	  day	  14	  from	  naïve	  and	  EAE-­‐
induced	  mice	  treated	  (i.p.)	  every	  other	  day	  with	  either	  100	  ng	  of	  1,25(OH)2D3	  in	  25	  µl	  
DMSO	   or	   25	   µl	   DMSO	   alone.	   To	   study	   the	   ex	   vivo	   response	   to	   neural	   antigen	  
stimulation,	   spleen	   cells	   were	   cultured	   (1X106/ml)	   in	   12-­‐well	   plates	   containing	   RPMI	  
with	   0	   or	   10	   µg/ml	   MOGp35-­‐55	   antigen.	   The	   in	   vitro	   response	   to	   1,25(OH)2D3	   was	  
determined	  by	  treating	  spleen	  cell	  cultures	  isolated	  from	  chronic	  	  EAE	  animals	  with	  0,	  5,	  
10,	  25,	  50,	  100	  or	  250	  nM	  1,25(OH)2D3.	  Supernatants	  from	  all	  spleen	  cell	  cultures	  were	  
harvested	  at	  72	  hr	  to	  measure	  the	  concentration	  of	  IFNɣ	  and	  IL-­‐12	  by	  ELISA.	  In	  short,	  96-­‐
well	  ELISA	  plates	  were	  coated	  with	  capture	  antibodies	  by	  incubating	  50	  µl/well	  of	  either	  
anti-­‐IFNɣ	   or	   anti-­‐IL-­‐12	   in	   .06M	   carbonate	   buffer	   (pH	   9.6)	   overnight	   at	   4°C.	   Excess	  
antibodies	   were	   washed	   with	   three	   rinses	   of	   PBST	   (PBS	   containing	   .05%	   Tween)	   and	  
excess	   protein	   binding	   sites	   blocked	   with	   3%	   BSA	   in	   PBS	   for	   1	   hr.	   Supernatant	   and	  
standard	  samples	  were	  plated	  in	  triplicate	  and	  incubated	  at	  4	  °C	  overnight.	  Plates	  were	  
rinsed	   with	   PBST	   three	   times	   and	   then	   incubated	   with	   biotin-­‐conjugated	   secondary	  
antibodies	   for	   2	   hr	   at	   room	   temperature.	   Excess	   antibodies	   were	   rinsed	   with	   three	  
washes	  of	  PBST	  before	   incubating	  plates	  with	  avidin-­‐alkaline	  phosphatase	   (1:5000)	   for	  
45	  min	  at	  room	  temperature.	  Plates	  were	  again	  rinsed	  and	  then	  developed	  over	  2	  hr	  by	  
incubation	  with	  1	  mg/ml	  p-­‐nitrophenyl	  phosphate.	  Absorbance	  was	  read	  at	  405	  nm	  and	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the	  concentration	  of	  IFNɣ	  and	  IL-­‐12	  in	  each	  sample	  calculated	  from	  the	  standard	  curve.	  
Examples	  of	  standard	  curves	  are	  provided	  (Fig.	  A4,5).	  
	  
Fig.	  A4.	  Example	  of	  IL-­‐12	  Alkaline	  Phosphatase	  ELISA	  	  
Standard	   curve	  of	   an	  Avadine-­‐Alkaline	  Phosphatase	  ELISA	  with	   IL-­‐12	   capture	   antibody	  




















Fig.	  A5.	  Example	  of	  IL-­‐1B	  Alkaline	  Phosphatase	  ELISA	  	  
Standard	   curve	  of	   an	  Avadine-­‐Alkaline	  Phosphatase	  ELISA	  with	   IL-­‐1B	   capture	  antibody	  


















Mixed	   brain	   cells	   were	   plated	   in	   an	   poly-­‐D-­‐lysein	   coated	   8-­‐well	   chamber	   slide	  
(BD	  Biosciences,	  Bedford,	  MA,	  USA)	  with	  200µl	  of	  DMEM	  medium.	  Experimental	  groups	  
were	   incubated	   for	   48	   hr	  with	   either	   100nM	   1,25(OH)2D3,	   4	   ng/mL	   IFNɣ,	   or	   100	   nM	  
1,25(OH)2D3	  and	  4	  ng/mL	  IFNɣ.	  One	  group	  was	  stimulated	  for	  48	  and	  1	  hr	  with	  1	  µg/ml	  
LPS	   and	   100	   mM	   ATP,	   respectively.	   Cells	   were	   incubated	   with	   fixative	   and	  
peremabilization	  solution	  at	  4	  °C	  for	  15	  min	  and	  then	  rinsed	  twice	  with	  cold	  PBS	  before	  
blocking	  with	  1%	  BSA	  in	  PBS	  at	  4	  °C	  for	  1	  hr.	  The	  slide	  was	  rinsed	  one	  time	  with	  cold	  PBS	  
before	  staining	  with	  primary	  anti-­‐peptidyl	  citrulline	  and	  MOG	  antibodies	  (both	  1:500)	  in	  
1%	  BSA	  at	  4	  °C.	  Following	  overnight	   incubation	  with	  primary	  antibodies,	  the	  plate	  was	  
rinsed	   three	   times	   with	   cold	   PBS	   and	   then	   stained	   with	   secondary	   antibodies	   (both	  
1:1000)	   in	   1%	  BSA	   at	   4	   °C	   for	   2	   hr.	   Cells	  were	   then	   rinsed	   three	   times	  with	   cold	   PBS	  
before	   addition	   of	   Vectashield	   mounting	   medium.	   Fluorescence	   of	   goat	   anti-­‐rabbit,	  
donkey	  anti-­‐mouse	  and	  DAPI	  were	  attained	  separately	  with	  green,	  red	  and	  blue	  filters,	  
respectively,	   using	   a	   Leitz	   DMRB	   microscope	   (Lecia	   Microsystems,	   Buffalo	   Grove,	   IL,	  
USA)	   outfitted	  with	   a	   RT	   Color	   camera	   (SPOT	   Imaging	   Solutions,	   Sterling	   Heights,	  MI,	  
USA)	  and	  then	  merged	  using	  SPOT	  software.	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Fig.	  A6.	  Example	  of	  triple	  staining	  of	  mixed	  brain	  cell	  culture	  	  	  
Image	  of	  nuclei	  (blue),	  MOG(red),	  citrulline	  (green)	  and	  areas	  of	  co-­‐staining	  (yellow).	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Fig.	  A7.	  Example	  of	  double	  staining	  of	  mixed	  brain	  cell	  culture	  	  	  
Image	   of	   MOG	   (red),	   citrulline	   (green)	   and	   areas	   of	   co-­‐staining	   (yellow)	   reveal	   co-­‐
localization	  of	  anti	  peptidyl	  citrulline	  and	  anti	  MOG	  antibodies.	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Flow	  Cytometery	  
DB29	  cells	  were	  plated	   (200,000/well)	   in	  a	  6	  well	   chamber	  slide	  with	  200	  µl	  of	  
DMEM	   medium.	   Experimental	   groups	   were	   incubated	   for	   48	   hr	   with	   either	   100	   nM	  
1,25(OH)2D3,	   4	   ng/mL	   IFNɣ,	   or	   100	   nM	   1,25(OH)2D3	   and	   4	   ng/mL	   IFNɣ.	   One	   set	   of	  
groups	  was	  stimulated	  for	  48	  and	  1	  hr	  with	  1	  µg/ml	  LPS	  and	  100	  mM	  ATP,	  respectively.	  
Cells	  were	  trypsinized	  and	  harvested	  then	  incubated	  overnight	  in	  250	  µl	  fixative	  solution	  
at	   4	   °C.	   The	   following	   morning	   cells	   were	   rinsed	   by	   adding	   500	   µl	   permebilization	  
solution	   to	   each	   sample	   and	   spun	   down	   before	   incubation	   with	   rabbit	   anti-­‐peptidyl	  
citrulline	   antibody	   (1:500)	   and	   mouse	   anti-­‐MOG	   antibody	   (1:500)	   in	   permebilization	  
solution	  for	  2	  hr	  at	  room	  temperature.	  Following	   incubation,	  cells	  were	  rinsed	  2x	  with	  
1%	  BSA	   in	  PBS	  before	   incubation	  with	  corresponding	  secondary	  antibodies	   (1:1000)	   in	  
permebilization	  solution	  for	  1	  hr	  at	  room	  temperature.	  Cells	  were	  then	  rinsed	  twice	  in	  




Fig.	  A8.	  Example	  of	  flow	  cytometry	  analysis	  of	  DB29	  immortalized	  oligodendrocytes	  	  	  
Analysis	  of	  citrulline	  (FL1-­‐H)	  vs.	  MOG	  (FL2-­‐H)	  positive	  DB29	  cells.	  Cell	  number	   in	  a	  few	  





Nitric	  Oxide	  Assay	  
Nitric	   oxide	   can	   be	   assayed	   using	   the	   Griess	   Reagent	   (Sigma).	   The	   amount	   of	  
nitric	  oxide	  reflects	  the	  activity	  of	  iNOS	  and	  thus	  inflammation.	  The	  test	  is	  performed	  by	  
plating	  50	  µl	  of	  Griess	  Reagent	  and	  50	  µl	  of	  standard	  or	  sample	  onto	  a	  96	  well	  plate	  and	  
reading	  absorbance	  at	  450	  and	  630	  nm	  once	  a	  colorimetric	  gradation	  appears.	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Fig.	  A9.	  Example	  of	  nitric	  oxide	  standard	  curve	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  VITAE	  
	  
Travis	  William	  McCain	  
	  
EDUCATION	  
8/13	  –	  9/14	  	   Indiana	  University	  |	  Indianapolis,	  IN	  
M.S.	   Candidate	   in	   Cellular	   Physiology.	   September	   2014.	   Coursework	   in:	   biochemistry,	  
physiology,	  neuroscience	  laboratory	  techniques,	  research	  ethics	  and	  biostatistics.	  
	  
6/13	  –	  8/13	  	   Boston	  College	  |	  Boston,	  MA	  
Coursework	  in:	  organic	  chemistry	  I	  &	  II	  lecture	  and	  laboratory.	  
	  	  
9/09	  –	  6/13	  	   Stanford	  University	  |	  Stanford,	  CA	  
B.S.	  in	  Engineering,	  Product	  Design.	  Program	  GPA:	  3.7/4.0	  
Coursework	   in:	   human-­‐centered	   design,	   mechanical	   engineering,	   biotechnology,	  
cognitive	  science	  and	  economics.	  	  
	  
6/12	  –	  8/12	  	   Peking	  University	  |	  Beijing,	  China	  &	  Liujiazhen,	  China	  
Studied	   cross-­‐cultural	   design	   in	   the	   resource-­‐poor	   setting	   of	   a	   rural	   Chinese	   village	  
through	  a	  team	  service	  project.	  
	  
1/12	  –	  3/12	   Stanford	  Bing	  in	  Washington	  |	  Washington,	  DC	  	  





10/13	  –	  7/14	   M.S.	  Graduate	  Thesis	  in	  Cellular	  and	  Integrative	  Physiology	  	  
Trained	  in	  neuroscience	  research	  techniques	  while	  investigating	  a	  link	  between	  vitamin	  
D	   and	   the	   expression	   of	   two	   genes	   involved	   in	   autoimmune	   and	   neurodegeneration	  
during	  multiple	  sclerosis	  pathogenesis.	  
	  
1/13	  –	  3/13	   Should	  We	  Use	  the	  Robot?	  |	  MS&E	  292:	  Health	  Policy	  Modeling	  
Reviewed	   published	   case	   studies	   to	   perform	   a	   cost-­‐effectiveness	   analysis	   of	   robot-­‐
assisted	   vs.	   open	   pediatric	   pyleoplasty.	   Sensitivity	   analysis	   revealed	   scenarios	   under	  
which	  robot	  assistance	  is	  and	  is	  not	  an	  incrementally	  affordable	  alternative.	  
	  
3/12	  –	  6/12	   William	  Morris	  Craft	  in	  Surgery	  |	  ME120:	  Philosophy	  of	  Design	  
Examined	  the	  erosion	  of	  proprioception	  in	  the	  evolution	  of	  least-­‐invasive	  surgical	  tools	  
and	  how	  this	  loss	  might	  affect	  surgeon	  skill	  acquisition	  and	  fulfillment.	  Analyzed	  primary	  
texts,	   interviewed	  surgeons	  and	  built	  an	   interaction	  to	  demonstrate	  surgical	  situations	  
where	  enhanced	  visual	  acuity	  cannot	  accommodate	  for	  a	  loss	  in	  haptic	  perception.	  
	   	   	  
EXPERIENCE	  
6/14–Present	   Complex	  Care	  Coordinator,	  Stanford	  Children’s	  Health	  |	  Stanford,CA	  	  
My	  responsibilities	  include	  developing	  management	  practices	  to	  ideate,	  implement	  and	  
evaluate	   new	   models	   of	   care	   delivery	   that	   help	   transition	   the	   hospital	   from	   fee-­‐for-­‐
service	   to	   value-­‐based	   reimbursement	   arrangements.	   I	   will	   be	   learning	   lean	  
management	  principles	  and	  fostering	  collaboration	  between	  the	  hospital	  and	  Stanford	  
Design	  School.	  
	  
9/11	  –	  8/13	   Product	  Design	  Consultant,	  Blue	  Ocean	  Ventures	  |	  Miami,	  FL	  	  
Prototyped	  and	  communicated	  new	  products	  and	  services	  using	  a	  user-­‐centered	  design	  
process.	   Coordinated	   development	   of	   client’s	   online	   services	   with	   web	   developer.	  
Iterated	   mechanical	   system	   design	   and	   developed	   reagents	   for	   water-­‐testing	   kiosk.	  
Coached	   client	   in	   Stanford’s	   iterative	   design	   process	   and	   co-­‐authored	   three	   pending	  
patents.	  
	  
1/12	  –	  3/12	   Intern,	  The	  World	  Bank	  Group|	  Washington,	  DC	  	  
Quickly	   became	   familiar	   with	   the	   field	   of	   behavior	   change	   design	   while	   managing	  
multiple	  projects	  including;	  meta-­‐analysis	  of	  prior	  Bank	  practices,	  organizing	  case	  study	  
findings	   for	   presentation,	   assisting	   outreach	   to	   potential	   partners	   of	   the	   practice	   and	  
grant	  writing.	  Worked	  closely	  under	  supervisor	   to	   iterate	  deliverables	  and	   incorporate	  
feedback.	  	  
	  
1/12	  –	  3/12	   Research	  Assistant,	  Center	  for	  Design	  Research|	  Stanford,	  CA	  
Assisted	  doctoral	  student	  with	  organization	  and	  presentation	  of	  dissertation.	  Developed	  
an	  understanding	  for	  team	  behaviors	  and	  design	  outcomes	  elicited	  through	  interaction	  
with	  low	  and	  high	  fidelity	  prototypes.	  
	  
9/07	  –	  9/11	   President,	  Midwestern	  Aquatics	  Inc.	  |	  Lizton,	  IN	  	  
Researched,	   designed,	   and	   developed	   a	   new	   material	   for	   growing	   coral.	   Secured	   a	  
contract	   to	   supply	  an	  aquaculture	   facility	  with	  over	  1/3	  million	  parts.	  Negotiated	  with	  
the	  client	  to	  develop,	  finance	  and	  implement	  specialized	  manufacturing	  equipment	  and	  




In	  Progress	   Travis	   W.	   McCain,	   Saravanan	   Kanakasabi,	   John	   J.	   Bright.	   A	   review	   of	  
epigenetic	  mechanisms	  in	  multiple	  sclerosis	  pathogenesis.	  	  
	  
8/14	   Travis	   W.	   McCain,	   Saravanan	   Kanakasabi,	   John	   J.	   Bright.	   In	   Submission	   2014.	  





	   	   	  
PRESENTATIONS	  &	  CONFERENCES	  ATTENDED	  
9/14	   Stanford	  Medicine	  X.	  Stanford,	  CA.	  
7/14	   Thesis	  oral	  defense.	  IU	  Health	  MRI	  Seminar.	  Indianapolis,	  IN.	  
7/14	   Indiana	  University	  Health	  Research	  Day.	  Indianapolis,	  IN.	  
2/12	   National	  Health	  Policy	  Conference.	  Washington,	  D.C.	  
9/11	   Poster	  presentation	  on	  Radical	  Breaks	  and	   Incremental	   Improvements	   in	  Team	  





8/13	   Philip	   William	   Root,	   Travis	   William	   McCain.	   61,869,917	   Self-­‐Service	   Kiosk	   for	  





9/12	  –	  12/12	   Teaching	  Assistant,	  U.S.	  Health	  Care	  Policy	  |	  Stanford,	  CA	  	  
Facilitated	   weekly	   discussion	   meetings	   with	   15+	   students	   to	   review	   course	   content.	  
Created	   curriculum	   materials,	   led	   review	   sessions,	   tutored	   students	   individually	   and	  
graded	  examinations.	  	  
	  
8/11	  –	  9/11	   Teaching	  Assistant,	  Design	  Thinking	  &	  Art	  of	  Innovation	  |	  Stanford,	  CA	  	  
Served	  as	  both	  a	  teaching	  and	  residential	  assistant	  to	  introduce	  students	  from	  a	  variety	  
of	  academic	  backgrounds	  to	  Stanford’s	  Design	  Thinking	  methodologies.	  Managed	  social	  




6/13	   “Grip	   Clip:	   Pencil	   Hero.”	   Injection	   molded	   part.	   Manufacturing	   &	   Finance.	  
Campaign	  funded	  on	  Kickstarter.	  
11/12	   “Icebergs.”	  Sculpture.	  Steel,	  acrylic,	  plaster,	  wax	  and	  water.	  	  
9/12	   “Preserves.”	  Sculpture.	  Steel,	  jello,	  glass,	  plaid	  fabric.	  	  
10/13	   “Homeless	  Humanity.”	  Portraiture	  &	  Writing.	  Displayed	  at	  Cantor	  Museum	  and	  
featured	  in	  Stanford	  Arts	  Review.	  
10/11	  	   “Care	  and	  Disease	  in	  Milne	  Bay,	  Papua	  New	  Guinea	  A	  Photo	  Essay.”	  Displayed	  at	  




1/14	  –	  7/14	   Clinic	  Volunteer,	  Gennesaret	  Free	  Clinic	  |	  Indianapolis,	  IN	  	  
Opened	  and	  closed	  clinic.	  Greeted	  patients	  and	  managed	  health	  records	  during	  visits.	  
	  
	  
	   	   	  
5/14	  –	  6/14	   Facilitator,	  Hugh	  O’Brian	  Youth	  Leadership	  (HOBY)	  |	  Indianapolis,	  IN	  	  
Facilitated	   discussion	   in	   a	   group	   of	   young	   high	   school	   students	   to	   develop	   leadership	  
confidence	  and	  skills.	  	  
	  
6/11	  –	  3/13	  	   Steering	  Committee	  Chair,	  Pacific	  Free	  Clinic	  |	  San	  Jose,	  CA	  	  
Connected	   underserved	   patients	   with	   specialty	   care	   providers	   after	   their	   clinic	   visit.	  
Tracked	   and	   reported	   effectiveness	   of	   referral	   process	   to	   propose	   improvements.	  
Directed	  scheduling	  and	  training	  of	  30	  volunteers.	  	  
	  
6/12	  –	  8/12	  	   Team	  Member,	  Cross-­‐Cultural	  Design	  for	  Service	  |	  Liujiazhen,	  China	  	  
Volunteered	   in	  rural	  China	  with	  a	  team	  of	  4	  peers	  from	  Shi	  Lanka,	  China	  and	  America.	  
Through	   interview,	   observation	   and	   prototype	   testing	   our	   team	   created	   and	  
implemented	  a	  program	  that	  uses	  art	  lessons	  as	  a	  medium	  for	  mentorship.	  	  
	  
7/11	  –	  8/11	  	   Clinic	  Volunteer,	  PNG	  Medical	  Project	  |	  Alotau,	  Papua	  New	  Guinea	  	  
Quickly	  learned	  to	  communicate	  with	  patients	  and	  present	  history	  and	  physical	  findings	  
to	   physicians.	   Researched	   and	   delivered	   a	   contextualized	   lecture	   on	   renal	   physiology	  





Lab	  Skills	   Techniques:	  EAE	  model	  of	  MS,	  rt-­‐qPCR,	  proliferation	  assay,	  FACs,	  western	  
blot,	   immunoslot	   blot,	   ELISA,	   proliferation	   assay,	   immunoflourscence,	  
dissection.	   Cell	   culture:	   neural	   stem,	   glial,	   macrophage,	   T	   cell	   &	  mixed	  
brain	  cell.	  
Design	  Skills	   User	   observation	   &	   interview,	   need	   finding,	   concept	   generation,	   rapid	  
prototype	  generation	  &	  testing,	  facilitating	  brainstorms,	  project	  planning,	  
cost	   modeling,	   sketching,	   CAD,	   technical	   writing,	   and	   Adobe	   Creative	  
Suite.	  	  
Honors	  	   Sam	  Walton	  Community	  Scholar.	  Awarded	   two	  Stanford	  Arts	  Grants	   for	  
photo	  essay	  works.	  Finished	  in	  the	  top	  2%	  at	  the	  largest	  half	  marathon	  in	  
the	  U.S.	  
 
	  
